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1 Abstract 
 
Adenovirus infections represent a considerable cause of life-threatening 
complications in immunocompromised patients. Among hematopoietic stem cell 
transplant recipients, mortality rates are particularly high, reaching values up to 80% 
(1-5). Available antiviral drugs such as nucleoside or nucleotide analogues suffer 
from efficacy against adenovirus infections or show severe side effects (6). Thus, the 
identification of alternative targets for therapeutic intervention is essential for 
improving the treatment of such infections. Unraveling the molecular interplay 
between the virus and its host cell may aid in the development of novel anti-
adenoviral treatment strategies.  
It has been shown that adenovirus interacts with the cellular RNA interference 
(RNAi) machinery by expressing small virus-associated (VA) RNAs. These RNAs are 
processed into micro(mi)RNA-like subfragments (mivaRNAs) which saturate the key 
enzymes of RNAi, Exportin-5, Dicer, and the Argonaute proteins that make up the 
RNA-induced silencing complex (RISC) (7, 8). mivaRNAs are suggested to target 
cellular mRNAs and thus alter host cell gene expression (9). In this study I 
investigated several aspects of these molecular interactions. 
To screen for mivaRNA target mRNAs, I used an immunoprecipitation assay to 
biochemically isolate RISC and its associated miRNAs and their target mRNAs from 
mivaRNA-transfected cells. Inspection of these putative targets by microarray 
analysis and bioinformatics target prediction software revealed a set of genes 
implicated in various biological functions such as signaling, metabolism and immune 
response. Targeting of these genes by the virus may be of importance for the 
successful establishment of a lytic viral infection or may aid in hiding from the host 
during a latent infection.  
Another proposed function of mivaRNAs is the protection of viral mRNA from 
cellular miRNA-mediated targeting (7). I employed RISC-immunoprecipitation to 
screen for the enrichment of viral mRNA in the presence or absence of mivaRNAs. 
When a mutant virus lacking the VA-RNAs was used to infect A549 cells, a set of 
adenoviral mRNAs was found enriched in RISC. This enrichment pattern differed 
from that obtained with the wild-type virus, possibly substantiating the proposed 
function of mivaRNAs to act as defense molecules against cellular RNA interference.  
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2 Zusammenfassung 
 
Adenovirale Infektionen in immunsupprimierten Patienten stehen im Zusammenhang 
mit einer hohen Anzahl an lebensbedrohlichen Komplikationen. Insbesondere nach  
hämatopoetischen Stammzelltransplantation können disseminierte Infektionen fatale 
Folgen haben und sind mit einer Mortalitätsrate von bis zu 80% assoziiert (1-5). 
Derzeit verfügbare Medikamente wie etwa Nukleosid- oder Nukleotidanaloga zeigen 
nur beschränkte Wirksamkeit gegen Adenovirusinfektionen oder führen zu 
schwerwiegenden Nebeneffekten (6). Deshalb ist es notwendig, alternative 
Angriffspunkte für eine therapeutische Intervention zu identifizieren, um die 
Behandlungsmöglichkeiten solcher Infektionen zu verbessern. Dabei könnte ein 
grundlegendes Verständnis des Wechselspiels zwischen einem Virus und seiner 
Wirtszelle zur Entwicklung neuer anti-adenoviraler Behandlungsstrategien  beitragen. 
 Es wurde gezeigt, dass Adenovirus mit der zellulären RNA-Interferenz (RNAi)-
Maschinerie interagiert. Dies erfolgt über die Expression von kleinen virus-
assoziierten (VA) RNAs. Diese RNAs werden zu miRNA-ähnlichen Subfragmenten 
(mivaRNAs) prozessiert, welche die Schlüsselenzyme der RNAi – Exportin 5, Dicer 
und den RNA-induced silencing complex (RISC) – sättigen (7, 8). Es wird 
angenommen, dass mivaRNAs die Genexpression ihrer Wirtszelle beeinflussen 
können, indem sie an zelluläre mRNAs binden (9). In dieser Studie wurden 
verschiedene Aspekte dieser molekularen Interaktionen untersucht.  
Um möglichen Ziel-mRNAs von mivaRNAs zu identifizieren wurde eine 
Immunpräzipitationsmethode angewandt. Dabei wurden Zellen mit mivaRNAs 
transfiziert und anschließend RISC Komplexe, sowie darin vorhandene miRNAs und 
deren Ziel-mRNAs biochemisch isoliert. Anschließend erfolgte eine kombinierte 
Microarray- und Bioinformatik-Analyse der potenziellen Ziel-mRNAs. Diese ergab ein 
Set an Genen, welche in verschiedenen biologischen Funktionen wie 
Signaltransduktion, Metabolismus und Immunantwort eine Rolle spielen. Man kann 
vermuten, dass ein Targeting dieser Gene durch mivaRNAs von besonderer 
Wichtigkeit für die erfolgreiche Etablierung einer lytischen Virusinfektion ist, oder 
dazu dienen kann sich während einer latenten Infektion vor dem Wirt zu verbergen.   
Des Weiteren wird vermutet, dass mivaRNAs als Schutzmechanismus für virale 
mRNAs fungieren (7). Die RISC-Immunpräzipitationsmethode wurde dazu 
verwendet, die Anreicherung viraler mRNAs in der An- oder Abwesenheit der 
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mivaRNAs zu untersuchen. Dabei wurde eine Virus-Mutante verwendet, welche die 
VA-RNAs nicht exprimieren kann. Wenn die Mutante anstelle des Wildtyp Virus für 
die Infektion von A549 Zellen verwendet wurde konnte gezeigt werden, dass 
bestimmte adenovirale Transkripte in RISC angereichert sind. Diese Beobachtung 
untermauert die für mivaRNAs vorgeschlagene Funktion als Mediatoren eines 
molekularen Schutzmechanismus gegen zelluläre RNAi. 
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3 Introduction 
 
3.1  Human adenoviruses 
 
3.1.1 Classification 
 
Human Adenoviruses (HAdVs) are members of the viral family Adenoviridae and 
belong to the genus Mastadenovirus. They have a linear, double-stranded DNA 
(dsDNA) genome and an icosahedral, non-enveloped capsid of approximately 90 nm 
in diameter (10). First isolated in the early 1950’s from adenoid tissue (11, 12) the 
family comprises nowadays more than 50 serotypes, which can be further 
subgrouped into six species (A to F), based on their DNA sequence or oncogenic and 
hemagglutinating properties (4, 13, 14)  
 
3.1.2 Clinical features 
 
Adenovirus infections in immunocompetent individuals are often subclinical and self-
limited. Diseases affecting the upper respiratory tract, the eyes as well as the 
gastrointestinal tract are the most frequent manifestations (14). Furthermore, chronic 
persistent infections in mucosal lymphocytes have been described, bearing the 
possibility for a reactivation of viral replication (15). Adenoviruses are highly prevalent 
in the human population since 80% of individuals are estimated to become infected 
early in life. Respiratory illness caused by adenovirus is common among children and 
people living in close proximity to each other such as military recruits (16, 17). The 
main routes of transmission are aerosolized droplets or by conjunctival inoculation. 
Furthermore, spread of the virus can occur by infected blood or tissue (14).  
 The lack of defence mechanisms against pathogens renders 
immunocompromised individuals susceptible to more severe disease upon 
adenovirus infection. Manifestations can include serious pneumonia, hemorrhagic 
cystits and meningoencephalitis. Finally, dissemination of the infection can lead to 
fatal outcome through multi-organ failure (3, 18).  
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Allogeneic stem cell transplantation (HSCT) is a current treatment option for 
patients suffering from haematological malignancies. However, the post-transplant 
period is characterized by an overall immunosuppression which is accompanied by a 
high risk for viral infections (19). The incidence rates for adenovirus infections 
following HSCT are alarmingly high. In a prospective multicenter trial including 130 
HSCT-recipients, 35 positive cases were diagnosed and among 36 patients who died 
during the study, nineteen were infected with adenovirus (20). A different study with 
similar results was conducted at the St. Anna Children’s Hospital, Vienna Austria, 
including 132 paediatric patients who underwent allogeneic stem cell transplantation. 
Overall, 27% of these patients were tested positive for adenovirus infection. In most 
cases, adenovirus belonged to group C. Particularly in the cohort of patients who 
were diagnosed positive for Adenovirus in the peripheral blood, which is an indication 
for disseminated disease, mortality rates were significantly higher compared to 
Adenovirus-negative patients, reaching a value of 82% (4).  
   
3.1.3  Therapy of adenovirus infections 
 
To counteract the severe clinical manifestation of adenovirus infections in 
immunocompromised patients, efforts were made to use existing antiviral drugs such 
as cidofovir or ribavirin to cure infected patients. 
The drug cidofovir, which is successfully used to clear infections with other 
viruses such as the cytomegalovirus (CMV), has been shown to be effective against 
adenoviruses as well (21). Cidofovir belongs to a class of antiviral drugs termed 
acyclic nucleoside phosphonates (ANP). These compounds are 2’,3’-
dideoxynucleotide analogues and are acting as polymerase inhibitors. ANPs show a 
higher affinity for the viral DNA polymerase than for the cellular isoform, which would 
restrict their action to virus-infected cells (6, 22, 23). However, due to accumulation in 
the renal proximal tubules, administration of ANPs is linked to severe nephrotoxic 
side effects (22).  
Ribavirin, which is another agent used in the treatment of viral infections has 
been evaluated for anti-adenoviral effects as well. Cell culture studies on the 
sensitivity of adenoviruses to Ribavirin revealed a species-dependent susceptibility. 
Among different serotypes from species A to F, an inhibitory effect could only be 
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observed for species C (24). Further studies have only revealed an overall low 
efficacy against adenoviruses (25).  
Adoptive immunotherapies using T-cells secreting Interferon-γ were shown to 
result in protection from complications related to adenovirus infections. However, T-
cell stimulation is laborious and the major disadvantage is the restricted availability of 
antigens required for their stimulation (reviewed in reference 26).  
Recently, alternative approaches for the inhibition of adenovirus multiplication 
in vitro were presented. An adenoviral vector-based system was used to express the 
Herpes simplex virus thymidine kinase (HSV-TK) gene in virus-infected cells. This 
would render adenovirus susceptible to the highly efficient anti-herpetic prodrug 
ganciclovir (27). Furthermore, successful efforts were made to knock down 
adenoviral gene expression by small interfering RNAs (siRNAs) (28). 
Despite these promising prospects, the fundamental understanding of the 
complex interaction between the virus and its host is still incomplete. Therefore, a 
complete comprehension of host-pathogen interplay will be crucial to provide novel 
opportunities for therapeutic interventions. 
 
3.1.4  Molecular organization of adenoviruses 
 
3.1.4.1 Structural characteristics 
 
A high-resolution view of the adenoviral capsid was revealed by X-ray 
crystallographic studies (29-31) (Fig. 1). The most abundant proteins of the capsid 
shell are the homotrimeric hexon (protein II), the penton base (protein III) and the 
protruding fibre proteins (protein IV). They are therefore termed the major 
components. Other structural elements of the capsid are the so-called minor proteins 
IIIa, VI, VIII and IX (32, 33).  Inside the virus core, the viral genome is associated with 
five other structural components (V, VII, µ, IVa2, and the terminal protein TP) (a 
detailed description can be found in reference 33).  
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Figure 1: Structural properties of adenovirus. (A) (Taken from reference 33). The 
organization of viral shell proteins is depicted. These consist of capsid and minor 
components defined by structural studies using cryo-electron microscopic and 
crystallographic techniques. The arrangement of the core proteins and the viral genome is 
rather speculative. (B) (Taken from reference 10). Transmission electron microscope image 
of a HeLa cell infected with adenovirus taken 48 hours post-infection. No, nucleolus; N, 
nucleoplasm; NE, nuclear envelope; C, Cytoplasm; M, Mitochondria; CM, cell membrane.  
 
3.1.4.2 The adenoviral genome organization 
 
The dsDNA genome consists of approximately 36 kb and is flanked by inverted 
terminal repeats which function as an origin of replication. A cis-acting packaging 
sequence is located next to the left terminal repeat. The genome of HAdVs contains 
five early transcription units (E1A, E1B, E2, E3 and E4), named after the time points 
when they are produced during the viral replication cycle (E = early, L = late). 
Furthermore three delayed early regions (IX, IVa2 and E2 late) as well as one late 
transcription unit are described. The latter is further processed into five late mRNAs 
(L1, L2, L3, L4 and L5). All of the transcription units are transcribed by RNA 
A B
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polymerase II and are subject to alternative splicing, which results in a complex and 
fine-tuned gene expression program.  
Additionally, depending on the serotype, adenovirus encodes one or two virus-
associated RNAs (VA RNAs), which are transcribed by RNA polymerase III. In 
general, the transcribed gene loci are asymmetrically distributed between the two 
DNA strands of the genome (Fig. 2). Thus, both strands encode different transcription 
units. A detailed description of the genome organisation of adenovirus is reviewed in 
reference 34. 
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Figure 2: The adenovirus transcription map. (A) (Taken from reference 35). Adenoviral 
mRNAs are transcribed from either the sense (upper) or the antisense (lower) strand of the 
double stranded DNA genome. The transcription map shows splice variants of the distinct 
transcripts. Additionally, the supposed mivaRNA binding sites are depicted. (B) The panel 
shows the distribution of predicted target sites of cellular miRNAs over the adenovirus 
genome. The predictions were calculated by TargetScan.  
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3.1.5 The adenovirus life cycle 
 
In most cases, adenovirus enters the host through the mouth, the nasopharynx or the 
ocular conjunctiva (23). As a first event in the replicative cycle, the virus attaches to 
the surface of cells located in its primary infection site by binding to primary high-
affinity receptors via the carboxyterminal knob domain of its trimeric fiber protein (13, 
34). For all adenovirus species except species B, the coxsackievirus and adenovirus 
(CAR) receptor has been shown to be an efficient docking site for the fiber protein 
(36). The main physiological function of this receptor is to mediate cell-to-cell 
adhesion through the formation of tight-junctions (37). Additionally, interactions with 
other receptors such as CD46, sialic adic, or lactoferrin have been shown to mediate 
attachment of different adenovirus species (reviewed in reference 38). 
Following interaction with the receptor, the virus is internalized by clathrin-
mediated endocytosis. This process is triggered by an additional interaction between 
the viral penton base and αv-integrins located on the cell surface (33). This results in 
a release of the fiber proteins and the uptake of the virus by clathrin-mediated 
endocytosis (39). After the maturation of clathrin-coated vesicles into endosomes, the 
virus particles eventually evade into the cytosol (40). Subsequently, the virion is 
disassembled by an ordered removal of structural proteins to allow the viral genome 
to enter the nucleus via the nuclear pore complex (34, 41, 42).  
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Figure 3: The adenovirus replicative cycle. (Adapted from reference 43). After attachment 
to a proper receptor on the host cell surface and internalization of the virus by endocytosis 
(1), the capsid is disassembled and the viral genome is translocated into the nucleus (2). The 
E1A mRNA is transcribed and exported into the cytoplasm where the E1A proteins are 
synthesized (4). These are shuttled back to the nucleus again, where they activate 
transcription of cellular as well as other early viral genes (5). In parallel, expression of the 
VA-RNAs is set on. The early viral genes are translated in the cytoplasm (6), and back in the 
nucleus, initiate replication of the viral genome (7). Late proteins are transcribed from de 
novo synthesized viral genomes (8) and exported from the nucleus. In the cytoplasm, 
structural proteins are synthesized (9) and imported into the nucleus. New immature capsids 
are assembled, and the viral DNA is packaged into them (10). As immature particles contain 
precursors of some structural components, they have to undergo cleavage reaction by the 
viral protease to allow the formation of fully infectious particles (11). The newly synthesized 
virions are released, usually accompanied by lysis of the host cell (12).  
 
Shortly after the viral DNA has reached the nucleus, the E1A transcription unit 
is being transcribed. The primary transcript is alternatively spliced and gives rise to 
2
1
3
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two major proteins with a respective length of 289 (termed E1A-13S) and 243 
(termed E1A-12S) amino acid residues (44). Sequence analysis of E1A identified four 
regions which have high sequence homologies among primate adenovirus 
subgroups and are therefore designated conserved regions (CR 1 to 4) (45). CR2 
has been shown to play a critical role in driving the host cell into S phase by 
sequestering the retinoblastoma protein (pRb) and its family members p107 and 
p130. This leads to the displacement of the E2F transcription factors, which can 
activate transcription of several genes necessary for S-phase entry (46). The 
displacement of pRb from E2F by E1A circumvents the mechanisms of normal cell 
cycling. A regular S-phase entry would implicate the phosphorylation of pRb by G1 
cyclin-dependent kinases (CDK) upon mitogenic stimuli. Furthermore, E1A has been 
shown to interfere with CDK-inhibitors (CKI) such as p16INK4a and p27KIP1, which 
would otherwise hinder cell cycle progression (47). This virus-induced cell cycling is 
essential for the progression of the virus lifecycle and provides an optimal 
environment for its replication.  
 However, irregular S-phase entry would result in an induction of the 
gatekeeper p53, which would lead to cell cycle arrest and apoptosis (48). Therefore 
E1B-55k, a protein which is translated from the E1B mRNA, acts in concert with 
E4orf6 (encoded in the E4 transcription unit) and several cellular proteins to form an 
ubiquitin ligase complex. The latter can mediate the polyubiquitination of p53 which 
leads to its proteasomal degradation (34).  
 Another mechanism to inhibit apoptosis is mediated through E1B-19k, which is 
the second protein originating from the E1B transcription unit. It is homologous to the 
apoptosis-regulating protein Bcl-2 and can counteract TRAIL- and Fas-induced 
programmed cell death (49).  
 The accumulation of E2 transcripts as a consequence of stimulation by E1A-
13S and the E2F transcription factor is a prerequisite for viral DNA replication. The 
E2-derived DNA-binding protein (DBP), the precursor terminal protein (pTP) and the 
DNA polymerase (Pol) cooperate with cellular factors to form the replication 
machinery (34, 50).  
The main function of the E3 genes is to suppress host defence mechanisms.  
A prominent mechanism involves E3-19K, which sequesters MHC-I in the 
endoplasmic reticulum to evade cytotoxic T-Lymphocyte (CTL) – mediated cell lysis 
(51). Additionally, the E3 region encodes the adenovirus death protein (ADP), which 
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facilitates the release of newly synthesized virions by catalysing virus-mediated cell 
lysis (52). Other proteins are involved in the inhibition of pro-apoptotic pathways (50). 
Moreover, adenovirus interferes with the cellular DNA damage response via 
proteins synthesized from the E4 region. This leads to genomic instability and is 
considered a ‘hit and run’ strategy, necessary to prevent nucleolytic cleavage of the 
viral genome (53-55). Besides that, the E4 unit encodes multiple functions, 
represented by a minimum of 18 distinct mRNAs derived from this region. These are 
involved in mRNA metabolism, facilitate replication of viral DNA and regulate 
apoptosis (50, 56).  
The late transcripts are produced at only low level during the early phase of 
infection. Simultaneously with viral DNA replication, an efficient expression of these 
genes is set on. The IX and IVa2 gene products, together with cellular transcription 
factors orchestrate the activation of the major late promoter. A large primary 
transcript is synthesized and processed into five groups of late transcripts (L1 to L5) 
coding mainly for structural components of the virion. Finally, viral genomes are 
packed into newly synthesized particles and the virus progeny is released into the 
cytoplasm. The host cell membrane is disintegrated and the viruses are released 
from the host cells (33, 34). 
 
3.1.6 The virus-associated RNAs 
 
Human adenoviruses encode a class of small non-coding RNAs transcribed by RNA 
polymerase III. These were in particular investigated in the group C adenoviruses, 
which possess two species of them, VA RNAI and VA RNAII. VA RNAs are about 
160 nucleotides in size and have a highly conserved secondary structure. Three 
structural characteristics are the terminal stem, the central domain and the apical 
stem-loop (57, 58). The transcription of the VA RNA genes is already initiated during 
the early phase of infection. During the late phase of infection, the transcription is 
enhanced, leading to the accumulation of about 1e+08 molecules of VA RNAI and 
approximately 1e+07 molecules of VA RNAII per infected HeLa cell (34). 
To investigate the impact of the VA RNAs on adenovirus replication, mutant 
adenoviruses type 5 (Ad5), lacking either the VA RNAI or the VA RNAII gene were 
used. An impaired growth compared to wild-type was observed for the VA RNAI 
mutant, but not for the VA RNAII mutant. However, when a double-mutant lacking 
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both, VA RNAI and VA-RNAII, was used, virus replication declined even further. This 
effect was explained by an inefficient translation of viral mRNAs during the late 
stages of infection (59, 60).  
Protein kinase R (PKR) is known to phosphorylate the translation initiation 
factor eIF2 in an inhibitory manner. This results in a general inhibition of protein 
synthesis. PKR is mostly activated by interferon-α and interferon-β as well as double-
stranded RNA (dsRNA) and thus represents a cellular anti-viral defence mechanism 
(reviewed in reference 61). However, VA RNAI prevents the activation of this 
response by binding to PKR in an inhibitory way, thus allowing the efficient translation 
of viral mRNAs (57, 62, 63) 
Finally, both VA RNAs were shown to influence the cellular RNAi pathway. 
The RNase III enzyme Dicer processed dsRNA into short RNAs of ~22 nucleotides 
(nt) in length. These are incorporated into the RNA-induced silencing complex (RISC) 
and guide the degradation of mRNAs containing complementary sequences (a more 
detailed description of the RNAi pathway can be found in the section “RNA 
interference”). It has been shown, that VA RNAs are processed into miRNA-like small 
RNAs (referred to as svaRNAs or mivaRNAs), which are incorporated into RISC and 
may target cellular mRNAs (9, 35, 64). Moreover, it has been reported that 
adenovirus is able to block the activity of Exportin-5, Dicer as well as RISC and 
probably Drosha at late stages of infection. Due to the high abundance of VA RNAs, 
this might be explained by oversaturation effects (7, 8).  
However, the extent to which mivaRNAs may contribute to a successful viral 
replication is still the object of intensive research. In particular the reliable 
identification of target genes remains the major challenge and is one major object of 
this thesis.  
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3.2  RNA interference 
 
In 1998, Mello and Fire could demonstrate for the first time, that dsRNA, when 
injected into the nematode Caenorhabditis elegans can interfere with endogenous 
gene activities in a highly efficient manner and were thus awarded the Nobel prize for 
Physiology or Medicine in 2006 (65, 66). Subsequently, it has been shown that the 
introduction of artificially synthesized short interfering RNAs (siRNAs) can trigger 
gene silencing also in mammalian cells (67). This discovery has shaped the future for 
the development of RNAi-based therapeutics (68). 
 
3.2.1 The canonical RNA interference pathway 
 
Sequence-specific mRNA degradation is mainly mediated by ~22-nt small interfering 
RNAs (67). These are incorporated into the RISC, where they can mediate silencing 
of their target genes either by repressive epigenetic modifications or post-
transcriptionally. Post-transcriptional silencing can occur either by direct cleavage of 
the target mRNA or by translational repression and subsequent mRNA decay. The 
mechanism induced depends on the degree of complementarity between the small 
RNA guide sequence and the target RNA. Small interfering RNAs showing perfect 
complementarity encourage nucleolytic cleavage by a core protein of RISC termed 
Argonaute 2 (Ago2). In contrast, particularly when nucleotides 2 to 8 of the guide 
sequence (seed sequence) show reduced complementarity to their target, 
translational repression and RNA decay is the preferred mechanism (Fig. 4). This 
mechanism is utilized by miRNAs (68). 
In the first step of miRNA biogenesis, primary (pri)-miRNAs are transcribed 
from miRNA genes by RNA polymerase II or III. pri-miRNAs form pronounced stem-
loop secondary structures. These stem-loops are cleaved off by the RNase III 
Drosha, which is part of the nuclear microprocessor complex. Next, a different RNase 
III, termed Dicer, processes pri-miRNAs to ~22 base-pair duplex RNA. Finally, one 
strand (the guide strand) is loaded into the RISC, whereas the unincorporated strand 
(passenger strand) is degraded. The incorporated strand acts as a mature miRNA by 
guiding the recognition of its target sequence (69). This usually results in silencing of 
the target gene, although it has been proposed that miRNAs may also enhance the 
translation of several proteins (70, 71). 
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3.2.2 The physiological functions of miRNAs 
 
Up to now, more than 1500 miRNAs encoded in the human genome have been 
proposed and the number of their putative target mRNA is consistently increasing 
(72-74). It is generally accepted that a controlled expression of miRNAs is 
indispensable for a variety of biological and cellular functions such as development, 
differentiation, cell cycle control, or apoptosis (reviewed in reference 75). It is 
therefore obvious, that a deregulated expression of one or more miRNAs might have 
a pathogenic outcome. In Alzheimer’s disease, decrease of the miR-29a/b-1 cluster 
is associated with an increase of the Aβ protein, the major component of amyloid 
plaques (76). Furthermore, in patients suffering from Parkinson’s disease, deficiency 
for miR-133b in midbrain tissue was reported, which may be conductive to the loss of 
midbrain dopaminergic neurons (77). Additionally, a role for miRNAs in the 
development of a wide range of cancers has been proposed. A prominent example is 
the downregulation of the let-7 family, which correlates with poor prognosis in lung 
cancer. Moreover, an implication of miRNA profiling for cancer diagnostics has been 
reported. Expression analysis allowed determining the developmental lineage and 
differentiation state of a tumor, as well as predicting the primary origin of metastasis 
(75). The essentiality of the miRNA pathway is further substantiated by the fact, that 
loss of Dicer or Argonaute proteins is lethal for most animals. For example in mice 
lacking Dicer, stem cell development is highly impaired, which results in embryonic 
lethality (78).  
 Despite rapid progress in the field of miRNA research, many biological 
functions of miRNAs are poorly understood and object of intensive research. Due to 
the facts that one miRNA may have multiple target mRNAs and one single mRNA 
might be targeted by several miRNAs creates an unmanageable complexity and the 
future challenge will be to unravel these labyrinthine interactions.  
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Figure 4: Mechanisms of cellular gene silencing. (Taken from reference 68). (A) In the 
first step the enzymes Drosha and DGCR8 catalyze the processing of primary microRNAs 
(pri-miRNAs) into precursor RNAs (pre-miRNAs). The latter are exported out of the nucleus 
by Exportin-5 (XPO5). In the cytoplasm they are recognized and processed into short double 
stranded RNA fragments by Dicer, which is part of the pre-RISC protein complex. One strand 
which is also referred to as the guide strand is selectively incorporated into the holo-RISC by 
Argonaute 2 (Ago2). The guide sequence can base-pair with corresponding target mRNAs. If 
a full complementarity is achieved (Fig. 4, left side), Ago2 catalyzes the cleavage and 
degradation of the target mRNA. If the guide strand is not fully complementary to its mRNA 
target, but base-pairing of the nucleotides 2-8 of the miRNA (defined as the seed region) 
occurs, mechanisms of translational inhibition take place. These can include the 
accumulation and non-sequence-specific degradation of silenced mRNAs in p bodies.  
(B) The introduction of artificial short hairpin(sh)RNAs (e.g., by the transfection of plasmid 
vectors), leads to the activation of the RNAi pathway. shRNAs are exported from the nucleus 
by XPO5. In the cytoplasm they are processed by Dicer and loaded into the RISC machinery.  
Those siRNAs can lead to the degradation of their target mRNAs by specific cleavage 
through Ago2.  
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(C) siRNAs in the nucleus which are base-pairing to promoter sequences can cause 
epigenetic modifications of chromatin which may lead to transcriptional gene silencing.  
 
3.2.3 Viruses and RNAi 
 
Besides being involved in gene regulatory functions, RNAi has been proposed to be 
a natural antiviral defence mechanism in invertebrates and plants. Virus-derived long 
dsRNAs are processed into siRNAs, which, after amplification, prime RNAi. However, 
this mechanism has not been shown for vertebrates yet. In vertebrates, the interferon 
(IFN) response is the primary antiviral defence mechanism of the innate immunity, 
leading to an overall halt of protein synthesis, cellular RNA degradation and in many 
cases death of the host cell (79). Nevertheless, RNAi may contribute to mammalian 
antiviral responses as well and this hypothesis is supported by a series of evidence. 
Matskevich et al. (80) could demonstrate that Dicer-knockdown in Influenza A-
infected cells led to an increase of virus production and enhanced apoptosis rates. 
Furthermore, the adenovirus VA RNAI and VA RNAII are processed by Dicer, 
incorporated into RISC and thus suppress RNAi (a more detailed description can be 
found in the section “The virus-associated RNAs”) (7). Finally, the HIV-1 trans-
activation-responsive RNA sequence (TAR) was shown to interfere with RNAi by 
sequestering the TAR RNA-binding protein (TARBP), which is essential for correct 
function of Dicer (81).  
General mechanisms to suppress RNAi may have evolved to escape inhibitory 
effects of host miRNAs on virus replication. Evidence for such mechanism comes 
from experiments which have demonstrated that interferon beta (IFNβ) rapidly 
changes the miRNA expression pattern in a cell by upregulating anti-viral miRNAs. 
Some of them were shown to have complementary sequences to hepatitis C virus 
(HCV) transcripts or the HCV genome. The induction of such miRNAs creates an 
antiviral environment within the cell, mostly by directly targeting HCV, leading to an 
inhibition of hepatitis C virus (HCV) replication and infection (Fig. 5) (82).  
A different study demonstrated that a panel of human miRNAs is enriched in 
primary resting CD4+ cells. Some of them were shown to target the 3’ ends of HIV-1 
mRNAs. In CD4+ cells, HIV-1 replication is inhibited and the virus favors to establish 
latent infections. To test the hypothesis whether cellular miRNAs may contribute to 
virus persistence, a combination of five antisense-inhibitors against putative antiviral-
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miRNAs were used. The transfection led to a substantial increase of HIV-1 protein 
and viral particles, assigning cellular miRNAs an important role in the suppression of 
virus replication (83).  
Recently, the existence of antiviral-miRNAs was further highlighted by similar 
experiments conducted for human papillomavirus and hepatitis B virus (84 and 
references therein).  
 Besides the proposed function of host-miRNAs to provide a defence against 
viruses by targeting their transcripts, a contrary role has been suggested as well. A 
prominent example affects the life cycle of HCV. miR-122 is specifically expressed in 
the liver where it represents about 70% of the whole miRNA population (85, 86). It 
has been proven, that the expression of miR-122 affects HCV replication in a positive 
manner (Fig. 5). This may provide a possible explanation for the tissue tropism of the 
virus (87, 88).  
In summary, different host miRNA expression patterns may either promote or 
delay the infection cycle of a virus and additionally may be involved in the 
establishment of latent infections.  
 
 
 
Figure 5: Potential Effect of Cellular miRNAs on Virus Replication. (Taken from 
reference 88). Viral replication may be affected in either a promoting of an inhibitory manner 
due to cellular miRNAs (purple) binding to viral RNAs (red). One example would be miR-122 
which was shown to promote the replication of Hepatitis C Virus (HPC). Furthermore, an 
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indirect promotion or limitation of virus replication by cellular miRNAs regulating their cellular 
target RNAs would be conceivable.  
 
 Another aspect of the interplay between viruses and RNAi comprises the field 
of virally encoded miRNAs. These small RNAs can directly modulate viral and/or 
cellular gene expression (Fig. 6) (88). The existence of viral miRNAs has been 
demonstrated for a wide range of nuclear DNA viruses comprising adenoviruses, 
Heliothis virescens ascoviruses, polyomaviruses and the whole herpesvirus family 
(89). One possible scenario involving virally encoded miRNAs is the interference with 
the host RNAi machinery by either competing for binding sites or by directly targeting 
host transcripts and thus creating an environment favourable for virus replication. 
Such an example would be the human cytomegalovirus, which encodes a miRNA 
targeting a cellular gene related to the major histocompatibility complex I. This leads 
to its downregulation and subsequent escape of the infected cell from natural killer 
cell-mediated destruction (90). The adenovirus-encoded small RNAs counteract 
cellular RNAi by saturating Exportin-5, Dicer, RISC and possibly Drosha (7, 8). A 
description of proposed biological functions of the VA RNAs can be found in the 
chapter “The virus-associated RNAs”.  
 Besides the interference with host-processes, viral miRNAs can also act as 
regulators of viral gene expression. Such mechanisms have been shown for 
herpesvirus, where the virally encoded miR-UL112-1 downregulates immediate-early 
genes. Suggested biological consequences of such regulators are optimisation of 
virus replication in different cellular environments by fine-tuning viral gene 
expression. Furthermore, downregulation of viral genes during the infection cycle 
may be crucial for the establishment and maintenance of persistent infections (91, 
92). Similar mechanisms would be conceivable for adenovirus as well, as it was 
shown that sequences complementary to the virus-derived mivaRNAs appear in the 
viral genome (Fig. 2A) (35). However, this assumption is rather speculative and 
intensively investigated.  
 Several ways by which viral miRNAs may strive to mediate the regulation of 
their own gene expression or to interfere with cellular processes are summarized in 
Fig. 6 and extensively reviewed in (88) and (93).  
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Figure 6: Suggested functions of viral miRNAs. (Taken from reference 88). (A) Virus-
encoded miRNAs are loaded into the RISC (green circle) and bind to viral mRNAs with 
perfect complementarity, which causes site-specific cleavage by Ago2. (B) Translational 
inhibition of viral transcripts by virus-encoded miRNAs. Viral miRNAs may have non perfect 
sequence complementarity to their targets mRNAs, which leads to repression of protein 
synthesis.(C) Virus-encoded miRNAs may disturb endogenous miRNA-regulated networks 
by directly targeting cellular mRNAs (red) or by mimicking the functions of cellular miRNAs 
(purple).  
 
3.2.4 Experimental approaches to study miRNA-mRNA regulatory networks 
 
The mechanisms by which miRNAs recognize their target sites were intensively 
studied during the last years, leading to the definition of rules for target site 
prediction. It is generally accepted, that the highly conserved Watson-Crick pairing 
between the seed region of the miRNA and the sequence of its target mRNA, usually 
located within the 3’ untranslated region (UTR), is sufficient to prime RNAi (94 and 
references therein). Based on this fact, attempts were made to design algorithms for 
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the prediction of miRNA binding sites. However, miRNA-mRNA interactions may be 
more sophisticated. It was for example shown that strong complementarity of the 
miRNA 3’ end can compensate for reduced binding of the seed region (95). 
Furthermore centered binding sites, base-pairing to 11-12 nucleotides in the central 
region of a miRNA, have been suggested (96). These dynamics in the definition of a 
target site is usually not considered in target prediction programs. To account for 
such alternative binding mechanisms will be a challenge for the future and will help to 
predict a more accurate spectrum of target sites.  
The predominant experimental techniques to screen for miRNA targets are to 
overexpress the miRNA of interest or to inhibit its expression, followed by analysis of 
differentially expressed genes. However both approaches are reported to yield high 
false positive rates, as indirect changes in gene expression cannot be distinguished 
from miRNA-mediated ones. Finally, mRNAs which are translationally repressed 
rather than cleaved upon miRNA targeting will not necessarily show altered gene 
expression upon overexpression or inhibition of a miRNA (97, 98).  
Given the limitations in computational miRNA target identification, efforts were 
made to develop novel approaches. Co-Immunoprecipitation of RISC along with its 
incorporated miRNAs and target mRNAs has been proven to be a powerful method.  
(99-104). The RNA immunoprecipitation (RIP)-Chip approach consists of an 
immunoprecipitation of RISC followed by microarray analysis of the target mRNAs. 
Modified protocols make use of deep sequencing instead of microarrays and are 
referred to as RIP-Seq (105). This method has been already successfully employed 
to identify the targetome of several viruses such as the Kaposi’s sarcoma-associated 
herpesvirus and Epstein-Barr virus (106). Here, a similar approach was used to study 
the overall impact of adenovirus on the targetome of an infected cell and to further 
elucidate the RNAi-coupled functions of mivaRNAs by identifying their targets genes.   
 Alternative approaches to RIP-Chip/RIP-Seq were introduced recently. The 
major difference is the use of ultraviolet light prior to immunoprecipitation to induce 
crosslinking of RNA to RNA-binding proteins. High-throughput sequencing of RNA 
isolated by crosslinking immunoprecipitation (HITS-CLIP), has been shown to be 
efficient, however the method has been mainly criticized for its low efficiency of 
crosslinking (98). A novel approach termed photoactive-ribonucleoside-enhanced 
crosslinking (PAR-CLIP) introduced by Hafner et al., uses photoactivatable 
nucleosides in cell culture medium to enhance the cross linking efficiency and may 
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hold promise for the future (107). Detailed information about the advantages and 
disadvantages of the distinct techniques used to assay miRNA-mRNA interaction can 
be found in reference 98. 
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4 Aims of this thesis 
 
Given the fact, that the adenovirus reproductive cycle is closely linked to cellular 
RNAi mechanisms, the goal of the present work was to gain a deeper insight into this 
complex interplay. Therefore emphasis was laid on the following points: 
 
1. Establishment of a RIP-assay as a reliable tool for studying miRNA-mRNA 
interactions 
 
2. Investigation if VA RNA-derived miRNAs target cellular mRNAs 
 Design and functional validation of artificially generated mivaRNAs 
(mivaRNA mimics) 
 Screening for cellular mRNA targeted by mivaRNA mimics using a RIP-
Chip approach and bioinformatic analysis 
 Validation of the RIP-Chip results with further molecular biological methods 
 
3. Characterization of the protective function of mivaRNAs on adenoviral mRNAs 
 
 Comparison of steady-state levels of viral transcripts of adenovirus type 5 
wild-type and a mutant lacking the VA RNA genes 
 Identification of viral transcripts targeted by miRNAs using the RIP-assay 
and computational prediction 
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5 Materials and Methods 
 
5.1 Cell culture 
 
Cells were usually maintained in 75 cm2 cell culture flasks at 37°C in a 5% CO2 
humidified atmosphere. A549 (human lung carcinoma cell line; ATCC CCL-185) and 
HEK293 (human embryonic kidney; ATCC CRL-1573) were maintained in DMEM 
high glucose medium with stable glutamine (PAA) supplemented with 10% fetal 
bovine serum (FBS; PAA). When reaching confluency, cell cells were split (1:10) 
using 0.25% trypsin/EDTA at 37°C for enzymatic cell removal. BJAB (EBV-negative 
B lymphoma cell line; (108)), THP-1 (Human acute monocytic leukemia cell line; 
ATCC TIB-202) and U937 (Human monocytic cell line; ATCC CRL-1593.2) were 
grown in RPMI 1640 (PAA) including 10% FBS (PAA). Cells were cryopreserved in 
the presence of DMEM media, supplemented with 10% dimethylsulfoxide (DMSO) 
and 20% DMSO and stored in liquid nitrogen. 
5.2 Amplification and purification of virus 
 
For propagation of adenovirus and adenoviral vectors, HEK293 cells were seeded 
into cell culture flasks and grown to approximately 70% confluence. Subsequently, 
virus was added and cells were incubated until showing cytopathic effects. After 
harvesting, adenovirus-containing cells were subjected to three freeze-thawing cycles 
to lyse the cells and to liberate virus particles. This was followed by centrifugation for 
15 min at 3000 rpm to pellet the cell debris. The supernatant was filtered through a 
0.45 μm filter. Adenovirus crude suspensions were purified by two rounds of standard 
CsCl gradient centrifugation. Adenoviral bands were isolated from the gradient and 
dialyzed against a buffer containing 10% glycerol (87%), 20 mM HEPES pH 7.3 and 
50 mM NaCl. Purified adenovirus was stored at -80°C after mixing in a ratio of 1:1 
with storage buffer (70% glycerol, 20 mM HEPES pH 7.3, 50 mM NaCl and 0.1% 
BSA). Infectious virus particle titers were determined on HEK293 cells by 50% tissue 
culture infective dose (TCID50) assays. 
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5.3 FACS 
 
In a first attempt to determine the infection efficiency of Ad5, a cytomegalovirus 
(CMV) promoter-controlled, enhanced green fluorescent protein (EGFP)-expressing 
recombinant adenoviral vector (pAD-CMV-EGFP, R. Klein, unpublished) was used. 
A549 cells were seeded at a density of 1e+05 cells per well of a 24-well plate the day 
before infection. Cells were infected with the adenoviral vector at a multiplicity of 
infection (MOI) of 1, 10, 30, and 50 in duplicate. The virus-containing medium was 
removed 4 hours post-infection; cells were washed with PBS and supplied with fresh 
medium. BJAB, THP-1, and U937 cells were infected at an MOI of 50, 100, 200 and 
500. Therefore, 1e+05 cells were collected and resuspended in 100 µl RPMI 1640 
medium w/o FCS. Infections were carried out in 96-well tissue culture plates. 4 hours 
post-infection the cells were transferred into microcentrifuge tubes. Cells attached to 
the surface of the plate were removed by treatment with 0.25% trypsin/EDTA at 
37°C. Cells were washed with PBS and supplied with fresh medium containing 10% 
FBS. 24 hours after infection, cells were harvested and analyzed with a FACS 
analyzer (FACS Calibur, Becton Dickinson) to determine the percentage of infected, 
EGFP-expressing cells.  
 
5.4 Vector construction 
 
Target vectors for mivaRNAs were generated by gene synthesis (Eurofins MWG, 
Ebersberg, Germany). Therefore, oligonucleotides corresponding to the mivaRNA 
target sequences were synthesized and cloned into psiCHECK-2 (Promega, 
Mannheim, Germany). Vector maps can be found in the section „Appendix“. 
 
5.5 Synthesis and transfection of mivaRNA mimics 
 
Single-stranded RNA oligonucleotides (Complementary sense and antisense strand 
of the respective mimic; Table 1) were purchased from RiboTask (Odense, 
Denmark). Oligonucleotides were annealed to produce dsRNA. Therefore, equimolar 
amounts (20 µM) of the two oligonucleotides were combined in a 75 µl reaction 
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containing 50 mM Tris (pH 7.5) and 100 nM NaCl in nuclease-free H2O. The solution 
was incubated at for 2 minutes at 95°C and allowed to slowly cool down to room 
temperature for one hour. Finally the solutions were cooled down to 4°C for another 
hour. The double-stranded mivaRNA mimics were analyzed by gel electrophoresis 
(Appendix) and stored at -20°C.  
 
Table 1: Sequences of the RNA oligonucleotides used for producing mivaRNA mimics 
RNA oligo name Sequence (5' to 3') 
mivaRI(A)-137-5‘  AGCGGGCACUCUUCCGUGGUCUGG 
mivaRI(A)-137-3‘  AGACAACGGGGGAGUGCUCCUUUU  
mivaRI(G)-137-5‘  GGGCACUCUUCCGUGGUCUGG 
mivaRI(G)-137-3‘  AGACAACGGGGGAGUGCUCCU 
mivaRII-138-5‘   GGCUCGCUCCCUGUAGCCGGA 
mivaRII-138-3‘  CGGAAACAGGGACGAGCCCC 
 
 
For RIP-assays, 3e+06 A549 cells were reverse transfected with 30 nM of the 
individual mivaRNA mimic or a non-targeting control siRNA using Lipofectamine 2000 
(Invitrogen/LifeTechnologies Austria, Vienna, Austria). For each transfection, 30 µL 
Lipofectamine 2000 was diluted with 1470 µL OptiMEM medium 
(Invitrogen/LifeTechnologies Austria, Vienna, Austria). After 5 minutes of incubation, 
1500 µL diluted Lipofectamine 2000 was mixed with 1500 µL of a specific siRNA mix. 
After 20 minutes of incubation, the mixes were combined with 12 ml of cell 
suspension and seeded into 10-cm cell culture dishes.  
 
5.6 Purification of nucleic acids 
 
Circular plasmid DNA was extracted with EasyPrep Pro Plasmid Mini-prep Kits 
(Biozym, Oldendorf, Germany) or EndoFree Plasmid Maxi Kit (Qiagen, Hilden, 
Germany). Total RNA was isolated using an RNeasy Mini Kit (Qiagen, Hilden, 
Germany) following the manufacturer’s instructions. Genomic DNA was digested 
using the RQ1 RNase-Free DNase (Promega, Mannheim, Germany) according to the 
standard protocol. Different RNA isolation methods were used in RNA 
immunoprecipitation experiments and are described in the respective section. The 
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nucleic acid concentration as well as the 260/280 nm and 260/230 nm ratios were 
assessed using a spectrophotometer (NanoDrop ND-1000, Thermo Fisher Scientific, 
Wilmington, DE, USA).  
 
5.7 cDNA synthesis and RT-qPCR 
 
Reverse transcription was carried out using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems/Life Technologies Austria, Vienna, Austria). 
mRNA levels were determined by TaqMan RT-qPCR assays carried out on a 
LightCycler® 2.0 (Roche Diagnostics, Vienna, Austria) instrument. RT-qPCR was 
performed with a Light Cycler® TaqMan® Master Mix (Roche Diagnostics, Vienna, 
Austria), 300 nM of the primers, 100 nM of the hybridization probes and 5μl of the 
cDNA sample in a total reaction volume of 20μl. Sequences of primer/probe sets 
specific for individual adenoviral or cellular mRNAs are listed in Table 2. 
Thermocycling conditions consisted of a pre-denaturation step at 95°C, followed by 
50 cycles of amplification: denaturation 10 sec at 95°C, annealing and elongation for 
15 sec at 60°C to 68°C.  
 
Table 2: Primer and probe sequences used for RT-qPCR assays 
Primer name Sequence (5' to 3') 
E1A 289R-cDNA-f1 GCATGTTTGTCTACAGTCCTGTGTC 
E1A 289R-cDNA-r1 GGCGTCTCAGGATAGCAGGC 
E1A 289R-cDNA-p1 AGGCTCCGGTTCTGGCTCGGG 
E1A-9S-cDNA-f1 AGCTGATCGAAGAGGTCCTGTG 
E1A 289R-cDNA-r1 GGCGTCTCAGGATAGCAGGC 
E1A 289R-cDNA-p1 AGGCTCCGGTTCTGGCTCGGG 
E1B_mRNA4-f1 GCGAGTGTGGCGGTAAACAT 
E1B_mRNA4-r1 GGCGGCTGCTCAATCTGTAT  
E1B_mRNA4-p1 TGCACCCGCGCTGAGTTTGGC 
E1B_mRNA5-f1 AATGTTGTACAGCAGCCGCC 
E1B_mRNA5-r1 TGGAGCCCATCACATTCTGAC 
E1B_mRNA5-p1 TCATATTTGACAACGCGCATGCCC 
Hex-cDNA-f1 CAGTCACAGTCGCAAGAGGAGC 
Hex-cDNA-r1 AGGTACTCCGAGGCGTCCTG 
Hex-cDNA-p1 ACCACTGCGGCATCATCGAAGGG 
IVa2-cDNA-f1 GGAAACCAGAGGGCGAAGA 
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IVa2-cDNA-r1 AGGGTCCTCGTCAGCGTAGTC 
IVa2-cDNA-p1 CTTGAGGCTGGTCCTGCTGGT 
ML-cDNA-f1 CAGCTGTTGGGCTCGCG 
ML-cDNA-r1 CGGGTTTCCGATCCAAGAGTAC 
ML-cDNA-p1 AGGACAAACTCTTCGCGGTCTTTCC 
DBP-cDNA-f1 GCGATATCAGGGGAGAAGGAA 
DBP-cDNA-r1 ACGACACGTCCTCCATGGTT 
DBP-cDNA-p1 TCGCGCTGCTCCTCTTCCCGA 
E3-cDNA-f1 CGCGACTCCGTTTCAACC 
E3-cDNA-r1 GTTCCCGGCAGGTAAGGAG 
E3-cDNA-p1 CCTCTCCGAGCTCAGCTACTCCATCAG 
E4-f1 ACAGGAAACCGTGTGGAATATAACA 
E4-r1 CCAACACACAGAGTACACAGTCCTTT 
E4-p1 TCCCCGGCTGGCCTTAAAAAGCA 
Pol-cDNA-f1 ATGGCCTTGGCTCAAGCTC 
Pol-cDNA-r1 GCGTAGGTTGCTGGCGAAC 
Pol-cDNA-p1 CGCCTCTGCGTGAAGACGACGG 
pTP-cDNA-f2 AAACCAACGCTCGGTGCC 
pTP-cDNA-r2 GGACGCGGTTCCAGATGTT 
pTP-cDNA-p2 CGCGCGCAATCGTTGACGCT 
GAPDH-f1 TGCACCACCAACTGCTTAGC 
GAPDH-r1 GGCATGGACTGTGGTCATGAG 
GAPDH-p1 CCTGGCCAAGGTCATCCATGACAACTT 
CCNE1-f1 GCTGCTTCGGCCTTGTATCA 
CCNE1-r1 GGAACCATCCACTTGACACAGTTC 
CCNE1-p1 CAAAAGGTTTCAGGGTATCAGTGGTGCG 
HMGA2-f1 AACCGGTGAGCCCTCTCCTA 
HMGA2-r1 CTCCAGTGGCTTCTGCTTTCTT 
HMGA2-p1 CCCAAAGGCAGCAAAAACAAGAGTCCC 
hRluc-f2 TGAGAGTGTCGTGGACGTGATC 
hRluc-r2 CACCATTTTCTCGCCCTCTTC 
hRluc-p2 CGAGTGGCCTGACATCGAGGAGGAT 
FLuc-f3 GGACCGCCTGAAGTCTCTGA 
FLuc-r3 CTCCGGCGTCGAAAATGTTA 
FLuc-p3 AAGGGCTACCAGGTGGCCCCAGC 
 
For the validation of microarray data, RT-qPCR was performed using the iQ SYBR 
Green supermix (Bio-Rad, Vienna, Austria). Therefore, 600 nM of each primer was 
combined with 5 µl cDNA in a 20 µl reaction. Thermocycling conditions consisted of a 
pre-denaturation at 95 °C, followed by 50 cycles of amplification: denaturation 10 sec 
33 
 
at 95 °C, annealing for 10 sec at 63°C and elongation for 15 sec at 72°C. Primer 
sequences are listed in Table 3: 
 
 
Table 3: Primers used for RT-qPCR to validate microarray data 
Primer name Sequence (5' to 3') 
CRIPAK-f1 GAGTCAGACGCTGTTACCGT 
CRIPAK-r1 ACGTTATCTCGAGGTGCAGAG 
IL12A-f1 TGCTCCAGAAGGCCAGACAA 
IL12A-r1 AAACAGGCCTCCACTGTGCT 
ISOC1-f1 CCGAGGAGTCGAGGTTCAC 
ISOC1-r1 TATGATCCCGGTTCGAGCGA 
TMEM222-f1 TGCTCTACGGGAAGTACGTCA 
TMEM222-r1 CCGGAGGTTAAAGACCAGGC 
GPR63-f1 CCGTAGGAAACCCCGACCTG 
GPR63-r1 GCCTGGTAGCCTGGATTGGT 
SUPT7L-f1 GGAGGAACCTGTGAGCGACA 
SUPT7L-r1 CCCAAGCACTCCCATAGGCA 
GUK1-f1 GTATGGCACGAGCAAGGTG 
GUK1-r1 GCGGCTGCACAGAGATGTAG 
PRR3-f1 CCTCGAAGGCTCAAAAGCTG 
PRR3-r1 CGGATTTGTCTTCCATAACCTGG 
LY6K-f1 ACCTGACTGCGAGACAACGA 
LY6K-r1 TGGGTTCTGGCACTCGAAAGT 
LEPROTL1-f1 TTTGATGCTTGGATGTGCCCT 
LEPROTL1-r1 GCCCGTTGTAAGAAAGATGGC 
SRI-f1 CAGAAGGCCCTGACAACAATG 
SRI-r1 GGCGATGTAGTCGTCGAAGG 
LGALS3-f1 TGGTGCCTCGCATGCTGATA 
LGALS3-r1 GCGTGGGTTAAAGTGGAAGGC 
RPL34-f1 TGGTGGTTCCATGTGTGCTAA 
RPL34-r1 GCTTGTGCCTTCAACACTTTC 
ZNF768-f1 AGGATGTGCAGAGTTCTGACG 
ZNF768-r1 TCGACTTCATAGTCCCCACTG 
COMMD1-f1 GCTACGGAGCCAGCTATATCC 
COMMD1-r1 GGTTTGAGCAGTCAAGAATGCC 
COMMD7-f1 TCTCTGAATTTGCCACCACCA 
COMMD7-r1 GCACCATTTGGAACCAGAAGG 
COMMD9-f1 CGAGGCAATTCTGGCTCTCTT 
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COMMD9-r1 GGCTTCGGTTCTCCAAGTAGAC 
NAT14-f1 GCGGGAGATGAGGGAAGATG 
NAT14-r1 GTTTTCCGTGTCCTTCACGC 
SMAGP-f1 ACCAGCCTCCTGACTACTCC 
SMAGP-r1 CTGCAATGAGTGCTGTGCTG 
BOK-f1 CAGTCTGAGCCTGTGGTGAC 
BOK-r1 GCATACAGGGACACCACCTT 
 
5.8 Luciferase reporter gene assay 
 
1.5e+05 HEK 293 cells were seeded into the wells of 96-well tissue culture plates. 
Cells were reverse transfected using Lipofectamine 2000 
(Invitrogen/LifeTechnologies Austria, Vienna, Austria). For one single transfection 
200 ng of pAdVantage vector (Promega, Mannheim, Germany) and 100 ng of the 
reporter vectors where used. mivaRNA mimics were used at a final concentration of 
10 nM per transfection. For each well, 0.5 µL Lipofectamine 2000 was diluted with 
24.5 µL OptiMEM medium (Invitrogen/LifeTechnologies Austria, Vienna, Austria) and 
incubated for 5 minutes. Next, 25 µl of a specific siRNA/reporter vector mix (diluted in 
OptiMEM) was added. After 20 minutes of incubation, the mixes were pipetted 
directly into the wells of a 96-well plate and freshly harvested cells were added. After 
24 hours, medium was exchanged and cells were incubated for another 24 hours. 
Firefly and Renilla luciferase activities were determined at 48 hours post-transfection 
using the Dual-Glo luciferase assay (Promega, Mannheim, Germany), following the 
manufacturer’s instructions. Briefly, 75 μL of Dual-Glo Reagent was added to cells 
grown in 75 μL medium, and after 10 min of incubation at room temperature, Firefly 
luciferase activity was measured. Next, one volume of Dual-Glo Stop & Glo reagent 
was added to each well, plates were incubated for an additional 10 min at room 
temperature and Renilla luciferase activity was determined. Luminescence was 
measured on a Wallac Victor 1420 Multilabel Counter (Perkin Elmer Austria, Brunn 
am Gebirge, Austria). Knockdown rates were calculated by normalizing Renilla 
luciferase activities to Firefly luciferase activities, and comparing dual-luciferase 
ratios between mivaRNA mimics and a non-targeting control siRNA and between the 
respective reporter-vectors and an unmodified psiCHECK™-2 vector (Promega, 
Mannheim, Germany).  
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5.9 Western blotting 
 
Cell lysates and beads-ribonucleoprotein (RNP) complexes from 
immunoprecipitations were mixed with NuPAGE® LDS Sample Buffer (NP0007; 
Novex®, Life technologies Austria, Vienna, Austria) and NuPAGE® Sample Reducing 
Agent (NP0009; Novex® Life technologies Austria, Vienna, Austria) at the 
recommended concentrations. Samples were heated to 70°C for 10 minutes prior to 
loading onto the gel.  To recover proteins from beads, samples were heated to 100°C 
for 5 minutes. The mixture was centrifuged at 2,000 x g for one minute at room 
temperature and the supernatant was used for electrophoresis. Proteins were 
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on NuPage® 
10% Bis-Tris gels (Invitrogen/Life Technologies Austria, Vienna, Austria) and 
transferred to nitrocellulose membranes (Whatman, Dassel, Germany). Membranes 
were stained with Ponceau S and subsequently blocked with blocking reagent 
(Roche Diagnostics, Vienna, Austria). Argonaute proteins were detected using the 
anti-pan Ago antibody (Clone 2A8, MABE56; Merck Millipore). A control antibody (sc-
32233; Santa Cruz Biotechnology Inc., Santa Cruz, USA) was used to detect GAPDH 
which served as a reference. Bands were visualized using a secondary fluorescent 
goat anti-mouse antibody (35521; Pierce Biotechnology Inc, Rockford, USA). 
Fluorescence was measured using a LI-COR Odyssey detection system (Li-Cor 
Biosciences, Lincoln, NE, USA). 
 
5.10  Preparation of cell lysates for 
immunoprecipitation 
 
Cells were collected and washed five times with PBS to remove traces of cell culture 
medium. Cells were lysed using an aqueous buffer containing 25 mM Tris-HCl, pH 
8.0 (15567027; Invitrogen/Life Technologies Austria, Vienna, Austria), 150 mM NaCl 
(AM9760G; Invitrogen/Life Technologies Austria, Vienna, Austria), 2 mM MgCl2 
(AM9530G; Invitrogen/Life Technologies Austria, Vienna, Austria), 0.5% IGEPAL® 
CA-630 (I8896; Sigma Aldrich St. Louis, MO, USA), 5mM DTT (43816; Sigma Aldrich 
St. Louis, MO, USA), protease inhibitors and 250U/ml RiboLock™ RNase Inhibitor 
(10389109; Fermentas, Glen Burnie, MD, USA). Cells were resuspended in lysis 
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buffer and incubated for 10 minutes on ice to lyse cells. 1 ml of lysis buffer was used 
to lyse ~6e+06 cells. Nuclei and debris were removed by centrifugation and the 
lysates were subjected to preclearing. 
5.11 Immunopurification of RISC and isolation of 
associated RNAs 
 
RISC and associated RNAs were isolated using an adapted protocol of a previously 
described RNA-immunopurification assay (available at 
https://ruo.mbl.co.jp/gtf/1/1/RN1001.pdf). For immunoprecipitation, an anti-pan Ago 
antibody (Clone 2A8, MABE56; Merck Millipore, Darmstadt, Germany) and a mouse 
IgG1 isotype control antibody (Clone 1E2.2, CBL610; Merck Millipore, Darmstadt, 
Germany) was used respectively. Prior to immunoprecipitation, antibodies (15 µg) 
were coupled to Protein G sepharose beads (Recombinant Protein G – Sepharose ® 
4B, 10-1242; Invitrogen/Life technologies Austria, Vienna, Austria). For one single 
Immunoprecipitation (IP), 25 µl of beads were washed three times with 1 ml of 
nuclease-free, ice-cold PBS (AM9624; Invitrogen/Life technologies Austria, Vienna, 
Austria). Antibodies were allowed to attach to the beads in 1 ml of nuclease-free PBS 
containing the protease inhibitors aprotinin (10 µg/ml, 10236624001; Roche, Vienna, 
Austria), leupeptin (5µg/ml, 11017101001; Roche, Vienna, Austria), 
phenylmethylsulfonyl fluoride (100µg/ml, P7626; Sigma Aldrich St. Louis, MO, USA) 
and pepstatin (1µg/ml, 10253286001; Roche, Vienna, Austria) at 4°C using an end-
over-end rotator. After 6 hours of coupling, to reduce unspecific binding, a blocking 
solution consisting of 1.2 mg/ml bovine serum albumin (A7906, Sigma Aldrich St. 
Louis, MO, USA) and 0.6 mg/ml yeast tRNA (10109517001, Roche, Vienna, Austria) 
was added. Beads were blocked overnight at 4°C under rotation. Just before 
immunoprecipitation, beads were washed once with PBS and twice with cell lysis 
buffer. Both buffers were supplemented with blocking solution.  
To reduce unspecific binding during immunoprecipitation, lysates were 
precleared: For one single IP, 60 µl of beads were washed three times with 1ml 
nuclease-free, ice-cold PBS and resuspended in 1 ml of nuclease-free PBS 
containing protease inhibitors. Beads were blocked under rotation overnight at 4°C in 
blocking solution. Immediately before preclearing, beads were washed twice with cell 
lysis buffer.  
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For preclearing, lysates were combined with beads and incubated under 
rotation for 1 hour at 4°C. 1/20 of the precleared lysate was used for isolation of total 
RNA (referred to as input) and another 1/20 was used for western blotting. The 
remaining precleared lysate was combined with the antibody-immobilized protein G 
sepharose beads and incubated with rotation for 3 hours at 4°C. 
To wash the antibody-immobilized protein G sepharose beads-RNP complex, 
beads were centrifuged at 2,000 x g for 1 minute at 4°C. The post-IP supernatant 
was stored in TRIzol reagent (15596-026; Life Technologies Austria, Vienna, Austria) 
for quality control. The beads were washed twice with lysis buffer containing blocking 
solution. Then, the beads were washed trice using an aqueous high-salt buffer 
containing 25 mM Tris-HCl pH 8.0 (15567027; Invitrogen), 900 mM NaCl (AM9760G; 
Invitrogen), 2 mM MgCl2 (AM9530G; Invitrogen), 1% IGEPAL® CA-630 (I8896; 
Sigma Aldrich), 5mM DTT (43816; Sigma Aldrich), blocking solution, protease 
inhibitors and RNase inhibitor. This was followed by washing twice with cell lysis 
buffer containing blocking solution. Finally the beads were washed with a low-salt 
buffer containing 25 mM Tris-HCl pH 8.0 (15567027; Invitrogen), 150 mM NaCl 
(AM9760G; Invitrogen), 2 mM MgCl2 (AM9530G; Invitrogen), 0.05% IGEPAL® CA-
630 (I8896; Sigma Aldrich), 5 mM DTT (43816; Sigma Aldrich), blocking solution, 
protease inhibitors and RNase inhibitor. 1/20 of the beads were used for western 
blotting, the remaining beads were subjected to RNA isolation.  
For RNA isolation, input samples and immunoprecipitates were homogenized 
after the addition of TRIzol. Input samples derived from virus-infected cells were 
additionally incubated for 30 minutes at 60°C with vortexing every 10 minutes to 
break open the capsids and allow for efficient digestion of genomic DNA. Chloroform 
(0.2 ml per 1 ml TRIzol) was added to homogenized lysates; samples were 
vigorously shaken for 15 seconds and incubated at room temperature for 3 minutes. 
After centrifugation at 12,000 x g for 15 minutes at 4°C, the aqueous phase was 
removed. 15 µg of glycogen (10814-010; Invitrogen/Life Technologies Austria, 
Vienna, Austria) was added to each sample. RNA was precipitated at -20°C for ~12 
hours after the addition of 2-propanol. Thereby, an amount of isopropanol 
corresponding to the volume of the aqueous phase was used. The RNA was 
collected by centrifugation (10 minutes at 12,000 x g) and the pellet was washed 
twice with 75% Ethanol. The pellet was resuspended in 20 µl of RNase-free H2O and 
incubated at 55°C for 10 minutes.  
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Contaminating DNA was digested using TURBO™ DNase (AM2238; Invitrogen/Life 
Technologies Austria, Vienna, Austria), according to the supplier’s protocol. DNase 
was inactivated by an additional TRIzol extraction.  
To remove yeast tRNA used in the blocking solution, RNA samples isolated 
from RISC and supposed to be used for microarray experiments were subjected to 
cleanup using the RNeasy MinElute Cleanup Kit (74204; Qiagen). 
 
5.12  Quantification of miRNA expression levels 
 
RNA was isolated using TRIzol as described in “Immunopurification of RISC and 
isolation of associated RNAs”. For miRNA quantification, miR-16 levels were 
determined using a pre-designed miRNA quantification assay. Briefly, 10 ng RNA was 
reverse transcribed using the TaqMan® MicroRNA Reverse Transcription Kit 
(4366596; Applied Biosystems/Life Technologies Austria, Vienna, Austria) following 
the manufacturer’s instructions. miR-16 levels were determined in a subsequent RT-
qPCR reaction carried out on a LightCycler® 2.0 (Roche Diagnostics) instrument. 
Therefore, 1.4 µl of the reverse transcription product was combined with 10 µl of 
Light Cycler® TaqMan® Master Mix (Roche Diagnostics) and 1µl TaqMan® microRNA 
Assay (4427975; Applied Biosystems/Life Technologies Austria, Vienna, Austria; 20 
x; forward primer, reverse primer and probe) in a 20 µl reaction. Thermocycling 
conditions consisted of a pre-denaturation step at 95 °C, followed by 50 cycles of 
amplification: denaturation 10 sec at 95 °C, annealing and elongation for 15 sec at 
60°C.  
 
5.13 RNA amplification 
 
The RNA obtained from RIP-assays was amplified using the Whole Transcriptome 
Expression kit (4411973; Ambion, Life Technologies Austria, Vienna, Austria). Briefly, 
first-strand cDNA synthesis was primed using a mixture of random hexamers and 
oligo(dT) primers containing the promoter sequence of  the T7 RNA polymerase as 
an extension. Next, single-stranded cDNA was converted to double-stranded cDNA 
using DNA polymerase contained in the kit. This was followed by in vitro transcription 
catalyzed by the T7 RNA polymerase using the second-strand cDNA as template. 
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Amplified cRNA was purified by using nucleic acid binding beads according to the 
manufacturer’s instructions. Second-cycle cDNA was synthesized using random 
primers. A buffer mix containing dUTP at a fixed ratio relative to dTTP was used, 
allowing the fragmentation of DNA for subsequent labeling. RNA template was 
hydrolyzed using RNase H and amplified second-cycle cDNA was purified using 
nucleic acids binding beads.  
 
5.14  Gene Chip microarray assay 
 
Purified second-cycle cDNA, containing dUTP residues, was fragmented using a 
combination of uracil DNA glycosylase (UDG) and apurinic/apyrimidinic 
endonuclease 1 (APE 1) followed by terminal labeling with biotin (WT Terminal 
Labeling Kit, Affymetrix, Inc., Santa Clara, CA, USA). Between 0.6 and 3.0 µg 
fragmented and labeled DNA was hybridized to an Affymetrix Human Gene 1.1 ST 
Array Plate. For hybridization, washing, staining and scanning an Affymetrix 
GeneTitan® system was used. Sample processing was performed at an Affymetrix 
Service Provider and Core Facility, “KFB - Center of Excellence for Fluorescent 
Bioanalytics” (Regensburg, Germany; www.kfb-regensburg.de). 
 
5.15  Microarray data analysis 
 
Probe set summarization, normalization and background correction was performed 
using the RMA (109) algorithm with the Affymetrix GeneChip Expression Console 
Software. Subsequent analyses were performed in R statistical environment using 
Bioconductor packages (110). Comparisons between different experiments were 
performed using a moderated t test from the “limma” package (111).  
 
5.16  Target site prediction 
 
Prediction of mivaRNA target sites in the human genome was performed using the 
“Targetscan” program with default parameters (72). 3’UTR sequences and Perl 
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scripts were downloaded from 
http://www.targetscan.org/cgibin/targetscan/data_download.cgi?db=vert_61. 
Coding sequences were downloaded from: ftp://ftp.ensembl.org/pub/release-
67/fasta/homo_sapiens/cdna/ 
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6 Results 
 
6.1 Establishment of RISC IP 
 
The reliable identification of mRNAs targeted by miRNAs remains a challenging field 
of research. Although recent advances in bioinformatics have facilitated the discovery 
of miRNA-mRNA interactions through the implementation of various prediction 
algorithms, these approaches still suffer from a variety of limitations. Since prediction 
software is based on probability calculations, actual miRNA-binding sites may be 
missed and thus the prediction may not comprise the entire spectrum of interaction 
partners or may lead to false positive results. To fill this technological gap, 
biochemical RIP-assays were employed, capable to identify RISC-incorporated 
miRNAs and their target mRNAs and are therefore contributing to a better 
understanding of miRNA-mediated regulatory processes in cells. Compared to 
conventional computing-based methods, they can facilitate the reduction of false-
positive and negative prediction rates. Nevertheless, bioinformatic analysis is 
essential to obtain optimal results and the combination between bioinformatics and 
biochemistry provides the most robust insight into miRNA target networks. However, 
such RIP-assays have to undergo stringent functional testing, ensuring accurate and 
error-free performance.  
 
6.1.1 Establishment of a dual-luciferase vector based reporter gene assay 
 
In a first approach I assessed the detection limits of the RIP-method by employing a 
reporter gene assay-based test system. Briefly, A549 cells were co-infected with 
adenoviral vectors bearing the Renilla luciferase (hRLuc) gene (pAd-Luc-as, R. Klein, 
unpublished) and an artificial miRNA known to directly target the 3’UTR of the hRLuc 
mRNA (mi+; pAd-FLuc-mi1, R. Klein, unpublished), respectively. A distinct vector 
carrying a non-targeting miRNA gene (mi-; pAd-mi-, R. Klein, unpublished) was used 
as a control. 24 hours and 48 hours post-infection, total RNA was isolated and 
reverse transcribed as described in “Materials and Methods”. Relative mRNA levels 
were determined by RT-qPCR. hRLuc mRNA levels were normalized to FLuc and 
GAPDH mRNA levels, respectively. 24 hours after co-infection with the luciferase and 
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the mi+ vector, a significant decrease in the relative hRLuc mRNA levels was 
observed. This effect was further enhanced at 48 hours post-infection. No significant 
reduction of hRLuc mRNA was noted when the non-targeting control vector was 
used, suggesting a miRNA-mediated silencing of the target gene (Fig. 7A). Thus, this 
system provides an appropriate readout for the establishment of a RIP-assay 
protocol. 
 
6.1.2 Quantification of RISC-associated luciferase target mRNA levels 
 
Next, the RIP-assay was established by co-infecting A549 cells with pAd-Luc-as and 
either pAd-FLuc-mi1 or the control vector pAd-mi-. At 24 hours post-infection, cells 
were lysed and RISC-complexes were isolated by immunoprecipitation using an 
antibody directed against the argonaute proteins Ago 1-4 (Fig. 7B). A distinct IgG-
isotype control antibody was used to determine background noise. A detailed 
description of the procedure can be found in the “Materials and Methods” section. 
Total RNA was isolated from 1/20 of the input fraction as well as from the 
immunoprecipitated fraction. RT-qPCR analysis of the input fraction revealed 
reduced relative hRLuc mRNA levels when cells were co-infected with the pAd-Luc-
as and the pAd-FLuc-mi1 vector compared to the co-infection with the negative 
control vector (Fig. 7C, left panel). Next, mRNA derived from the immunoprecipitated 
fraction was quantified. Relative mRNA levels were determined by normalizing these 
values to the levels of the input fraction. When the cells were co-infected with the 
pAd-Luc-as and the pAd-FLuc-mi vector, hRLuc mRNA obtained from the 
immunopurified RISC complex was found enriched over the control IP (Fig. 7C). No 
significant enrichment was obtained when the non-targeting miRNA vector was co-
introduced. Furthermore, no enrichment was detected for the housekeeping gene 
GAPDH. This gave rise to the conclusion that GAPDH expression is not or at least 
not extensively regulated by endogenous miRNAs in A549 cells and was thus 
considered as a constant factor for calculating mRNA enrichments. In this 
experiment, the relative hRLuc mRNA isolated from the Ago-IP was approximately 9-
fold enriched over GAPDH when the cells were co-infected with pAd-Luc-as and the 
vector producing the targeting miRNA. A significant enrichment was neither detected 
when the isotype-control antibody was used, nor when the cells were co-infected with 
the non-targeting miRNA (Fig. 7D). Furthermore, immunoblot analysis of the 
43 
 
immunprecipitated fraction showed specific enrichment of argonaute proteins. An 
antibody against GAPDH was used as a control (Fig. 7E).  
 
 
Figure 7: Establishment of a RIP-assay for the identification of miRNA targets. (A) An 
artificially induced miRNA-mRNA interaction served as an initial readout for setting up the 
assay. A549 cells were co-infected with distinct adenoviral vectors. A dual-luciferase based 
reporter vector bearing the Renilla (hRLuc) and the Firefly luciferase (FLuc) genes (pAd-Luc-
as) together with a vector encoding a miRNA targeting hRLuc (mi+) were used. A distinct 
AAAAAA
Input fraction
target mRNA quantification
miRNA mimic or non-targeting control
3‘ UTR Luciferase vector
co-infection
RISC
Nucleus
Cell lysis
miRNA + mRNA purification
miRISC isolation
(anti-AGO1-4)
Total RNA isolation
B
Input Ago-IP
WB: AGO1-4
WB: GAPDH
Input
0.0
0.5
1.0
1.5
R
e
la
ti
v
e
 R
e
n
il
la
 m
R
N
A
le
v
e
ls
Co-infection with mi+
0.00
0.01
0.02
0.03
0.04
0.05
Ago-IP
IgG-IP
R
e
la
ti
v
e
 m
R
N
A
le
v
e
ls
Co-infection with mi-
0.00
0.01
0.02
0.03
0.04
0.05
Ago-IP
IgG-IP
R
e
la
ti
v
e
 m
R
N
A
le
v
e
ls
Beads
0
5
10
15
Ago
IgG
F
o
ld
e
n
ri
c
h
m
e
n
t
o
v
e
r
In
p
u
t 
/
G
A
P
D
H
 m
R
N
A
C
D E
***
48h p.i.
0.0
0.5
1.0
1.5
R
L
u
c
/F
L
u
c
m
R
N
A
ra
ti
o
A 24h p.i.
0.0
0.5
1.0
1.5
R
L
u
c
/F
L
u
c
 m
R
N
A
ra
ti
o
*
*
44 
 
non-targeting miRNA gene (mi-) served as a negative control. At 24 and 48 hours post-
infection hRLuc mRNA levels were determined by RT-qPCR, respectively. 24 hours after co-
infection with the Luc and the mi+ vector, a significant decrease of relative hRLuc mRNA 
levels could be observed. This effect was even more elevated at 48 hours post-infection. In 
both cases, no significant decrease could be detected when Luc was introduced together 
with mi-. mRNA levels were normalized to GAPDH and FLuc. The mRNA levels are shown 
relative to the hRLuc mRNA obtained upon infection with Luc alone. (B) Schematic 
representation of the RIP-assay. Cells are co-infected with the Luc and the mi+ vector. The 
mi- vector is used as a negative control. Cells are lysed and RISC complexes containing 
miRNAs and their target mRNAs are immunopurified using antibodies against argonaute 1-4 
(anti-Ago1-4) coupled to sepharose beads. Total RNA is isolated from a part of the total cell 
lysate (referred to as Input fraction) and serves as a reference for subsequent normalization 
of RNA levels. Furthermore, miRNAs and their target mRNAs are isolated from the 
immunopurified RISC complexes and target mRNAs are quantified by RT-qPCR. (C) RT-
qPCR analysis of the two distinct fractions obtained from an immunoprecipitation experiment. 
An anti-Ago1-4 antibody (Ago-IP) or an IgG-control antibody (IgG-IP) was used for 
immunoprecipitation. Cells were either co-infected with pAd-Luc-as and pAd-Luc-mi1 or pAd-
Luc-as and pAd-mi- vectors. Left panel: Relative input hRLuc mRNA levels after co-
transfection with pAd-Luc-mi1 compared to the co-transfection experiments in which the non-
targeting control miRNA was used. Middle panel: mRNA levels obtained from the 
immunoprecipitates were normalized to the respective input levels. Right panel: Cells co-
infected with the non-targeting miRNA. (D)  The mRNA levels obtained from the 
immunoprecipitates were first normalized to their respective input levels and then normalized 
to GAPDH mRNA levels (E) Quality control for the immunoprecipitation of RISC complexes. 
1/20 of the input fraction was used for western blotting using an anti-Ago1-4 antibody. A 
GAPDH antibody was used as control. 
 
6.1.3  Enrichment of endogenous miRNAs and target mRNA 
 
To further evaluate the assay performance I investigated whether endogenous 
miRNAs and their target mRNAs can be enriched by IP. It has been proven that the 
Cyclin E1 (CCNE1) mRNA is post-transcriptionally regulated by miR-16 in A549 cells. 
This results in mRNA degradation and thus downregulation of the CCNE1 mRNA 
levels (112). Thus, I investigated if CCNE1 mRNA and its corresponding targeting 
miRNA miR-16 can be enriched by the established method. RIP-assay of A549 cells 
revealed highly significant enrichments (~18,600 fold; p-value = 0.0098) of miR-16 
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levels over the miRNA levels obtained using the IgG control antibody (Fig. 8A). In line 
with this result, also the CCNE1 mRNA was enriched when the antibody against the 
argonaute proteins was used for IP (~10.5 fold; p-value = 0.001) (Fig. 8B). Since 
again no significant enrichment of GAPDH was observed, relative CCNE1 mRNA 
levels were normalized to the respective mRNA levels of the housekeeping gene.  
This resulted in a normalized enrichment over input of approximately 10-fold (Fig. 
8C).  
 
 
Figure 8: Enrichment of endogenous miRNAs and their target mRNAs. A549 cells were 
grown to confluence for 30 hours and subsequently subjected to RIP-assay. Ago-IP: Relative 
mRNA levels obtained in RISC IPs performed with the pan-Ago antibody. IgG-IP: Relative 
mRNA levels obtained when the IgG-control antibody was used for IP (A) Enrichment of miR-
16 by immunoprecipitation of Argonaute 1-4. The amount of miRNA was determined by RT-
qPCR and normalized to the level obtained from the input fraction. Input levels were set at 1. 
(B) Relative mRNA levels of CCNE1, a prominent target mRNA of miR-16. GAPDH mRNA 
levels served as a control gene determined by RT-qPCR. All mRNA levels were normalized 
to their respective input values. (C) Right panel: Normalized enrichment of relative CCNE1 
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mRNA levels obtained through Ago-IP. CCNE1 mRNA levels measured by RT-qPCR were 
first normalized to the input values and then relativized to GAPDH mRNA levels. Right panel: 
Normalized enrichment of CCNE1 mRNA obtained when an IgG control antibody was used 
for IP.   
 
Altogether, these results provide a proof-of-principle that miRNA-targeted mRNAs 
can be reliably identified by the RISC-IP approach. Thus, this method was 
subsequently employed to investigate interactions between mivaRNAs and cellular 
mRNAs.  
 
6.2 The interplay between adenoviral gene products 
and the cellular RNA interference machinery 
 
6.2.1  Identification of cellular mRNAs targeted by virally encoded miRNAs 
 
The adenovirus encoded VA RNAs have been shown to be processed into functional 
miRNAs which are incorporated into RISC (9). However, little is known about their 
cellular target genes. Efforts to identify putative targets were made by Aparicio et al. 
(64). They performed microarray analysis to elaborate a set of genes which were 
downregulated in the presence of mivaRNAs. Furthermore, they combined this 
genomic approach with bioinformatics to substantiate their findings. However, the 
major problem of such conventional approaches is their inability to distinguish 
between direct miRNA-mediated downregulation of gene expression or secondary 
effects. RIP-Chip, however, allows to identify true RISC-associated mRNAs.  
 
6.2.2 Functional validation of mivaRNA target vectors 
 
In a first approach, to evaluate the ability of synthetic mivaRNA mimics to mediate 
regulation of gene expression by Ago2-guided target mRNA cleavage I performed 
dual-luciferase reporter gene assays. Therefore I used genetically engineered 
reporter constructs based on the psiCHECKTM-2 vector. The latter contains the 
sequences of the Renilla and the Firefly luciferase gene under control of distinct 
promoters. A multiple cloning site (MCS), located downstream of the Renilla 
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luciferase open reading frame, allows insertion of target sequences, resulting in a 
fusion mRNA. I used reporter constructs containing the target sequences for VA 
RNA-derived mivaRNAs in their 3’ UTR (Fig. 9A). Upon transfection into cells, active 
luciferase protein is produced, which can be quantified by measuring luminescence 
(Fig. 9B). However, when active, mivaRNAs are present, they would specifically 
recognize their target sequence fused to the Renilla luciferase mRNA and thus 
promote its degradation. This would result in abolished synthesis of Renilla luciferase 
protein and consequently Renilla luciferase activity (Fig. 9C).  
 
6.2.3 Validation by using the pAdVantage vector 
 
To assess the reliability of the reporter gene assay, I used the pAdVantage vector 
(Promega), which harbors the VA RNAI and VA RNAII genes. HEK293 cells were 
either transfected with the empty psiCHECKTM-2 vector alone, or co-transfected with 
the pAdVantage vector and the distinct psiCHECKTM-2 vectors containing the 
mivaRNA target sites. These vectors are referred to as pmiVAI3, pmiVAI5, pmiVAII3 
and pmiVAII5 and a detailed description can be found in the “Appendix” section. A 
co-transfection experiment using the pAdVantage vector combined with the empty 
psiCHECKTM-2 vector served as a negative control. I could observe a highly 
significant decrease in luciferase activity upon co-transfection of pAdVantage and the 
vectors bearing the target sequences for mivaRNAs derived from both strands of VA 
RNA I. I also detected a pronounced decrease, when the vector carrying the target 
sequence for the mivaRNA derived from the 3’ end of VA RNA II was co-transfected.  
However, luciferase activity was not abolished when the vector containing the target 
sequence for the 5’end of VA RNAII-derived mivaRNAs was used (Fig. 9D). This 
results is consistent with the literature, as Xu et al. could demonstrate that only a 
small fraction (about 2,5%) of the RNAs derived from the 5’ end of the VA RNAII is 
incorporated into the RISC complex (35).  
 
6.2.4 Confirmation by using adenovirus type 5 wild-type 
 
Next, I confirmed these results by repeating the experiment with adenovirus-infected 
cells. Therefore, HEK293 cells were again transfected with the reporter gene 
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constructs bearing the target sites for mivaRNAs. The next day, cells were infected 
with Ad5 wild-type and luciferase activity was assayed 24 hours post-infection. The 
luciferase levels dropped significantly as a consequence of the production of 
mivaRNAs (Fig. 9E). The most significant decrease could be observed for pmiVAI3 
(88% ± 0.187%, p-value < 0.0001), indicating that the mivaRNA produced from the 3’ 
strand of VA RNAI was the most efficient in terms of silencing its target mRNA. 
Furthermore I noted a significant down-regulation of luciferase activity also for the 
pmiVAI5 as well as the pmiVAII3 target vector. These observations are in accordance 
with the previous results and suggest that the adenovirus-encoded mivaRNAs 
recognize their target sequences in a highly efficient manner. Interestingly, in this 
experimental setup, a significant downregulation of the luciferase gene could also be 
observed for the target vector of the mivaRNA derived from the 5’ strand of VA RNA 
II. This effect was not observed in previous experiments, in which the pAdVantage 
vector was used instead of adenovirus. However, one simple explanation might be 
that much higher levels of mivaRNAs were present in the virus-infected cells 
compared to cells transfected with the plasmid. This would render it likely that 
inefficient RISC-incorporation may be compensated by a high abundance of the 
molecule.  
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Figure 9: Functional validation of mivaRNA mimics. To functionally validate the ability of 
mivaRNAs to recognize and degrade their target mRNAs, a dual-luciferase reporter gene 
assay was performed. The reporter constructs are based on the psiCHECKTM-2 vector. 
Statistical evaluation of data was performed using the unpaired Student’s t-test, considering 
a p-value less than 0.05 as statistically significant. (A) The binding sites for mivaRNAs were 
inserted into the 3’ MCS of the Renilla luciferase gene (hRLuc). (B) Upon transfection into 
cells, the hRLuc mRNA is produced and translated into the corresponding protein, whose 
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activity can be quantified by measuring the luminescence. (C) In the presence of RISC-
incorporated mivaRNAs, the hRLuc mRNA is recognized by the active RISC and catalytically 
cleaved by argonaute 2. This leads to mRNA degradation and to reduced protein levels 
resulting in diminished luminescence. (D) HEK293 cells were co-transfected with the 
pAdVantage vector and luciferase reporter constructs containing the target sequences for 
mivaRNA I and II either derived from the 3’end or the 5’ end of the corresponding VA RNA 
(pmiVAI3, pmiVAI5, pmiVAII3, pmiVAII5). The unmodified psiCHECKTM-2 vector was used as 
a control. At 24 hours post-transfection, luminescence of Firefly and Renilla luciferase was 
measured. Renilla luciferase luminescence levels were normalized to Firefly luciferase 
luminescence levels. (F) HEK293 cells were transfected with luciferase reporter constructs. 
The unmodified psiCHECKTM-2 vector was used as a negative control. The next day, cells 
were infected with Ad5 wild-type. At 24 hours post-infection, the enzymatic activities of the 
Firefly and Renilla luciferases were determined. All Renilla luciferase luminescence 
measurements were related to the corresponding Firefly luciferase values. These normalized 
Renilla luciferase levels are depicted as relative to the luciferase levels in uninfected cells.  
No significant decreased in Renilla luciferase activity could be observed when the unmodified 
psiCHECKTM-2 vector was used. (n = 3; mean values ± SD; * p<0.05, ** p<0.01, ***p<0.0001, 
n.s. = not significant) 
 
6.2.5 VA RNA mimic-mediated down regulation of target sequence 
 
To investigate the biological functions of the adenovirus-derived mivaRNAs, 
mivaRNA mimics were designed. It has been shown that the VA RNAs can give rise 
to distinct small RNAs in dependence of the cleavage site of Dicer. Thereby, the 
small RNAs mivaRNAI-137 and mivaRNAI-138 are among the predominantly 
produced mivaRNAs, termed after their starting position in the VA RNA molecule 
(Fig. 10A) (35). Furthermore, transcription of VA RNAI can start from two different 
sites, hence giving rise to even more mivaRNA species. Named after their first 
nucleotide, VA RNAI(A) and VA RNAI(G) have been described (113 and references 
therein). In this study I used small double stranded RNA oligonucleotides mimicking 
mivaRNAI(A)-137 and mivaRNAI(G)-137 as well as mivaRNAII-138. These artificially 
synthesized small RNAs represent a reliable tool to perform gain-of-function studies 
on miRNAs and hence allow an extensive functional analysis of the different 
mivaRNAs.  
51 
 
I first tested the ability of the mimics to direct RISC-catalyzed target mRNA 
cleavage in luciferase reporter gene assays. Therefore I used again the genetically 
engineered reporter constructs bearing the mivaRNA target sequences. HEK293 
cells were co-transfected with the mimics and their corresponding target vectors. A 
non-targeting siRNA was used as a negative control in all experiments and a siRNA 
against the adenovirus pTP mRNA, co-transfected together with its target vector was 
used as a positive control (“Appendix”).  mivaRNA mimics derived from the 3’ region 
of VA RNAI performed best (Fig. 10B). Again, these results are consistent with the 
literature as it has been shown that the 3’ end-derived mivaRNAs are incorporated 
into RISC at much higher efficiency. Despite its inefficient incorporation, the 5’end-
derived mivaRNA has been shown to catalyze the cleavage of its target mRNA in a 
more efficient way (113). This may compensate for its low incorporation efficiency 
and may thus provide an explanation for the reduced luciferase levels in both cases. 
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Figure 10: VA RNA mimic-mediated down regulation of target sequence. Adenovirus 
encodes two short RNAs termed VA RNAI and VA RNAII. During the infection cycle, they are 
processed into miRNAs by Dicer, and are incorporated into RISC (7). (A) (Adapted from 
reference 7). Secondary structure models of VA RNAI and VA RNAII are depicted. 
Sequences located next to the 5’ end as well as the 3’ end of both, VA RNAI and VA RNAII 
gives rise to mivaRNAs. Several mivaRNAs mimics were designed in analogy to these 
regions and are illustrated by the red and the green lines. (B) mivaRNA mimics  promote 
Ago2-mediated cleavage of their target mRNAs. HEK293 cells were co-transfected with the 
mivaRNA mimic and a psiCHECKTM-2 vector carrying the corresponding target sequence 
inserted into the Renilla luciferase gene (pmiVAI3, pmiVAI5, pmiVAII3, pmiVAII5). A non-
targeting siRNA was used as a negative control (crtl. siRNA).  Renilla and Firefly luciferase 
activities were determined 48 h post-transfection. Relative Renilla luciferase levels of cells 
only transfected with the target vectors were set at 100%. Renilla luciferase relative to Firefly 
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luciferase activities were calculated (n = 3; mean values ± SD; ** p<0.01, ***p<0.0001, n.s. = 
not significant).  
 
6.2.6 Genome-wide screening for targets of virally-encoded miRNAs 
 
The RIP-assay established was used to identify putative target genes of mivaRNAs. 
Since the mivaRNAs derived from VA RNAI showed better performance in luciferase 
assays, they were used for further experiments. A549 cells were transfected with 
mivaRNAI(A)-137 and mivaRNAI(G)-137 mimics as well as with a non-targeting 
negative control siRNA.  At 24 hours after transfection, cells were harvested and 
RISC complexes including miRNAs and their target mRNAs were isolated using the 
anti-pan ago antibody as described in the previous sections. Additionally, lysates 
from A549 cells infected with Ad5 wild-type or mock for 30 hours were subjected to 
RISC-IP.  RNA was purified from the immunoprecipitated complexes as well as from 
the whole cell lysates, amplified and treated as described in “Materials and Methods”. 
mRNA levels were quantified by microarray analysis.  
After data normalization, mRNA levels obtained from the immunoprecipitated 
fractions were compared. Isolated RISC complexes from experiments in which 
mivaRNA mimics were transfected may contain their target mRNAs but additionally 
also contain mRNAs targeted by cellular miRNAs. In a first approach, to exclude 
these endogenous miRNA-mRNA interactions target mRNA levels obtained from 
mivaRNA-transfected cells were compared to targets from cells transfected with the 
non-targeting control siRNA. In comparison to the control, 4633 genes were found 
enriched in RISC complexes isolated from mivaRNAI(A) mimic-transfected cells. 
When RISC complexes isolated from mivaRNAI(G) mimic-transfected cells were 
compared, a list of 4920 enriched genes was obtained. 4966 genes were found 
enriched in RISC complexes isolated from Ad5-infected cells, compared to mock-
infected cells. To reduce false positives stringent criteria for the selection of miRNA-
targets were introduced. First, a transcript had to be enriched > 2.0 to be considered 
a target with a statistical significance of p<0.05. 18 genes fulfilled this criterion. To 
define rules for the selection of putative candidate genes, the enrichment on beads 
over input was calculated. Finally, we used RIP-Chip-data from Ad5- or mock-
infected cells and elaborated a list of differentially RISC-enriched genes. Genes 
enriched in virus-infected cells, were compared to the putative mivaRNA-targets 
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identified by RIP-Chip. Strikingly, most of the genes could be found enriched greater 
than 2-fold in the virus-infected fraction as well. Thus, the incorporation of this set of 
mRNAs into RISC does also occur during a natural adenovirus infection and is not an 
artifact of the particular assay setup. The enrichment values were visualized in a 
heatmap analysis (Fig. 11).  
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Figure 11: Heatmap showing differences (Δ) between microarray groups. Comparisons 
between mRNA levels obtained from immunoprecipitated RISC complexes (Ago) from either 
cells transfected with a negative control (NC) siRNA or a mivaRNA mimic (137(A) or 137(G)) 
are depicted. Furthermore transcript levels obtained from RISC complexes 
immunoprecipitated from adenovirus infected cells (AgoAdV) compared to mock infected cells 
(AgoMock) are shown and were used as a criterion for candidate selection. Comparison to the 
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respective input levels are shown and were used as a further quality control. Arrows indicate 
the transcripts that were selected for further analysis. 
 
The analysis revealed 18 putative mivaRNA targets which were selected for 
validation. Additionally, COMMD1 was included in the analysis, as it was the top-
ranked gene in TargetScan analysis (Table 3 and Table 4). A subset of transcripts 
showed mimic-specific enrichment. For example CRIPAK was enriched over negative 
control only when the mivaRNAI(A) was used. On the other hand GRP63 seemed to 
be targeted to a higher extend by mivaRNAI(G) than by mivaRNAI(A). This specific 
enrichment is presumably a result of targeting by the 5’ strand of the distinct mimics. 
This strand is specific for each mimic and differs in its seed sequence. 
 
Table 3: Putative targets of mivaRNA-137(G) identified by RIP-Chip. List of putative 
target genes selected for further validation sorted according to the enrichment following 
mivaRNAI(G)-137 transfection. 
Name 
Ago NC - Ago 
137 (G) 
Ago Mock - 
Ago AdV 
Enrichment 
over Input 
mivaRNA 
137(G) 
Enrichment 
over Input NC 
Enrichment 
over Input AdV 
Fold change 
Input 
IL12A 5.66 2.43 8 1.4 2.68 0.99 
ISOC1 4.76 8.75 9.19 1.29 14.83 0.67 
TMEM222 3.01 4.5 4.96 1.3 3.03 0.79 
NAT14 2.58 3.05 4.69 1.8 20.68 1 
GPR63 2.55 5.7 2.97 1.17 9 1.01 
SUPT7L 2.5 8.75 2.43 0.88 2.55 0.91 
GUK1 2.43 18.51 3.97 1.54 30.91 0.94 
PRR3 2.41 2.83 3.66 1.29 4.56 0.85 
LY6K 2.3 3.56 5.78 2.04 4.86 0.81 
COMMD9 2.23 3.1 2.41 1.05 2.13 0.97 
LEPROTL1 2.03 12.13 1.16 0.54 5.28 0.94 
BOK 1.93 1.52 4.76 1.87 8 0.75 
SRI 1.92 3.03 1.01 0.48 1.18 1.99 
RPL34 1.79 56.1 0.64 0.35 12.55 1.66 
SMAGP 1.79 4.23 2.45 1.24 16.68 1.43 
COMMD1 1.17 7.94 0.34 0.3 1.25 1.03 
ZNF768 1.13 4.99 2.13 2.04 8.63 1.07 
LGALS3 1.01 2.04 1.47 1.48 6.15 1.01 
CRIPAK 0.91 8.51 0.72 0.82 3.68 1.02 
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Furthermore, consistent with our expectations the two distinct mimics shared a 
common group of putative targets. It has been shown, that mivaRNAs derived from 
the 3’-strand of the VA RNAI are loaded into the RISC complex with high efficiency. 
Moreover it has been demonstrated that Dicer cuts VA RNAI(A) and VA RNAI(G) at 
the same position. This implicates, that both mivaRNA(A)-137-3‘ and mivaRNA(G)-
137-3‘ contain the same seed sequence (Fig. 10A; described in more detail in 
reference 113). Thus, the common group of targets will likely be targets of the 3’-
derived strands.   
 
Table 4: Putative targets of mivaRNA-137(A) identified by RIP-Chip. List of putative 
target genes selected for further validation and sorted according to the enrichment following 
mivaRNAI(A)-137 transfection.  
Name 
Ago NC - Ago 
137 (A) 
Ago Mock - 
Ago AdV 
Enrichment 
over Input 
mivaRNA 
137(A) 
Enrichment 
over Input NC 
Enrichment 
over Input AdV 
Fold change 
Input 
CRIPAK 3.89 8.51 3.86 0.82 3.68 0.82 
IL12A 3.56 2.43 4.79 1.4 2.68 1.04 
ISOC1 3.39 8.75 5.78 1.29 14.83 0.76 
LGALS3 2.83 2.04 4.23 1.48 6.15 0.99 
GUK1 2.69 18.51 4.38 1.54 30.91 0.95 
TMEM222 2.6 4.5 3.97 1.3 3.03 0.85 
NAT14 2.14 3.05 3.94 1.8 20.68 0.98 
LY6K 2.13 3.56 5.24 2.04 4.86 0.83 
ZNF768 2.11 4.99 4.26 2.04 8.63 1.01 
LEPROTL1 2.1 12.13 1.19 0.54 5.28 0.96 
SRI 1.99 3.03 1.08 0.48 1.18 0.87 
PRR3 1.79 2.83 2.43 1.29 4.56 0.95 
COMMD1 1.77 7.94 0.72 0.3 1.25 0.74 
SUPT7L 1.74 8.75 1.66 0.88 2.55 0.92 
GPR63 1.72 5.7 1.99 1.17 9 1.01 
BOK 1.72 1.52 3.97 1.87 8 0.81 
RPL34 1.66 56.1 0.59 0.35 12.55 0.98 
COMMD9 1.51 3.1 1.62 1.05 2.13 0.97 
SMAGP 1.43 4.23 1.97 1.24 16.68 0.9 
 
6.2.7 Validation by using TargetScan 
 
The putative targets were combined to TargetScan predictions, to possibly set an 
additional rule for selection of candidate genes. This algorithm searches for 
conserved matches of the seed region of a given miRNA. We used the seed 
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sequences of the distinct mimics and obtained a list of predicted target sites. The 
output was divided in sites located within the UTR and the coding sequence (CDS). 
Both possibilities were taken into consideration and we divided our analysis into 
genes with predicted UTR-hits and CDS-hits. For many genes, multiple hits within the 
same mRNA were predicted. Thus, we used the minimum score as a criterion to 
predict the targeting efficacy. 
Next, these hits were combined to the genes identified by the microarray 
analysis. Strikingly, most of the candidates identified by RIP-Chip were among the 
predicted mivaRNA targets in the TargetScan analysis, substantiating their validity 
(Table 5).  
 
Table 5: Predicted target sites on transcripts identified by RIP-Chip. Seed sequences of 
the distinct mivaRNA strands were used as input.  
Name 
minimal score 
cds 
hitCount cds 
minimal score 
utr 
hitCount utr Putative targets 
BOK -0.49 1 -0.47 1 mivaI137(A)-3'; mivaI137(G)-3' 
COMMD1 -0.63 3 -0.62 1 mivaI137(A)-5' 
COMMD9 -0.12 5 - - mivaI137(A)-3'; mivaI137(G)-3' 
CRIPAK -0.33 129 - - mivaI137(A)-5'; mivaI137(G)-5' 
GPR63 -0.19 3 - - mivaI137(A)-3'; mivaI137(G)-3' 
GUK1 -0.23 5 - - mivaI137(G)-5' 
IL12A -0.44 5 -0.45 1 mivaI137(A)-3'; mivaI137(G)-3' 
LEPROTL1 -0.24 6 -0.08 1 mivaI137(A)-5'; mivaI137(G)-5' 
LGALS3 -0.22 3 - - mivaI137(A)-5'; mivaI137(G)-5' 
LY6K -0.46 9 -0.35 3 mivaI137(A)-3'; mivaI137(G)-3' 
PRR3 -0.29 119 -0.19 4 
mivaI137(A)-3'; mivaI137(G)-3'; mivaI(A)137-
5' 
RPL34 -0.16 5 - - 
mivaI137(A)-3'; mivaI137(G)-3'; 
mivaI(G)137-5' 
SMAGP -0.18 7 - - mivaI137(A)-3'; mivaI(A)137-5' 
SRI -0.38 3 -0.18 2 mivaI137(A)-3'; mivaI137(G)-3' 
SUPT7L -0.24 9 -0.22 2 mivaI137(A)-5' 
TMEM222 -0.32 23 -0.32 4 
mivaI137(A)-3'; mivaI137(G)-3'; 
mivaI(G)137-5' 
ZNF768 -0.31 4 - - mivaI137(A)-5' 
ISOC1 - - - - - 
NAT14 - - - - - 
 
However, the accuracy of some predicted sites has to be carefully re-evaluated. In-
depth analysis of the predicted regions revealed redundant predictions, resulting in 
an overestimation of the number of predicted hits. Furthermore, a region 
complementary to mivaRNA137(A)-5’ in the NAT14 mRNA, a putative target which is 
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not among the predicted transcripts, could be manually identified. Furthermore, the 
occurrence of several transcript variants is not taken into consideration by the 
algorithm. Thus, additional binding sites may be missed. Nevertheless, some of the 
putative targets were predicted correctly. COMMD1, which has been found enriched 
in the presence of mivaRNA137(A) but not of mivaRNA137(G) is indeed predicted to 
be targeted by the 5’ strand of mivaRNA137(A).  
 
6.2.8 Validation of RIP-Chip data by RT-qPCR  
 
The putative miRNA targets identified by RIP-Chip were validated using RT-qPCR 
assays. Therefore, levels of transcripts isolated from RISC of the mivaRNA mimic- 
transfected cells were determined by RT-qPCR and compared to levels of transcripts 
isolated from RISC of the control siRNA-transfected cells (Fig. 12).  
In summary, I could reproduce most of the enrichment values obtained from 
microarray analysis. The enrichment over the negative control condition was 
statistically significant in most cases. Also the mimic-specific enrichment for the 
transcripts ZNF768 and CRIPAK could be shown. Nevertheless, some transcripts 
such as COMMD1 and COMMD7 revealed no significant enrichment over the 
negative control using the RT-qPCR assays. This might be either due to suboptimal 
priming conditions or due to false positive array data. Thus, re-evaluation of the 
dataset by an additional independent experimental setup is required. 
Furthermore, the enrichment of putative target mRNAs in adenovirus-infected 
cells compared to mock-infected cells was assessed as well (Fig. 13). The 
enrichment obtained was generally concordant with our previous data. Although 
some enrichment values were not statistically significant, they tended to reflect the 
same pattern obtained in previous experiments. In some cases, the missing 
significance can be explained by the detection limit of RT-qPCR. Some transcripts 
could not be measured in both replicates isolated from the mock-infected cells. In 
these cases, a CT-value of 40 was used to calculate the theoretical minimum amount. 
The differences between the replicates may arise when slightly different amounts of 
RNA are used for the initial RNA amplification. Since this method relies on a 
minimum amount of RNA for each transcript, especially low abundant mRNAs may 
not be efficiently amplified and thus fall below detection limits in subsequent assays.  
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Interestingly, the enrichment values tended to be generally higher than in the 
experiment where the mimics were used. This might be due to the high abundance of 
mivaRNAs at this stage of infection, suggesting less molecules per cell in the 
transiently transfected cells. Moreover additive effects implicating other virally 
encoded miRNAs sharing the same targets are conceivable.  
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Figure 12: Validation of microarray data by RT-qPCR. Fold enrichment between RISC-
isolated transcripts from cells transfected with a negative control siRNA or a mivaRNA mimic 
respectively were determined by RT-qPCR. Data was normalized to GAPDH (n = 3; mean 
values ± SD). Statistical evaluation of data was performed using the unpaired Student’s t-
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test, considering a p-value less than 0,05 as statistical significant (*) and less than 0,01 as 
highly statistical significant (**). 
Figure 13: Validation of microarray data by RT-qPCR. Putative mivaRNA targets were 
quantified using RNA isolated from RISC-complexes adenovirus-infected cells. Mock-
infected cells were used as a control. All data were normalized to GAPDH housekeeping 
gene (n = 2; mean values ± SD). Statistical evaluation of data was performed using the 
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unpaired Student’s t-test, considering a p-value less than 0,05 as statistical significant (*) and 
less than 0,01 as highly statistical significant (**). 
 
Together, these results provide additional evidence for the biological function of 
mivaRNAs to act as viral miRNAs. The RIP-Chip analysis revealed a set of putative 
genes related to distinct cellular functions which might be targeted by these small 
RNAs. This interaction may constitute a virus-host interaction, advantageous for the 
virus in terms of protection from cellular antiviral responses, prolonging the infection 
cycle, or establishment of a latent state.  
 
6.3  Identification of viral gene products targeted by 
cellular miRNA 
 
Adenovirus modulates the RNAi pathway by expressing its VA RNAs. The latter are 
oversaturating Dicer, Exportin-5 and RISC, and thus interfere with the host RNAi 
pathway. One suggestion is that such a mechanism may have evolved under 
selective pressure to counteract cellular miRNAs which would provide a cellular 
defense mechanism against viruses (7). In this last part of the project, I studied 
whether viral mRNAs are targeted by cellular miRNAs. This would help to elucidate 
the role of cellular RNAi as a general defense mechanism against viruses or as a 
regulator of the adenovirus replicative cycle.  
 
6.3.1  Determining optimal conditions for adenovirus multiplication 
 
In subsequent experiments different cell lines were used, which were chosen 
according to their properties to promote adenoviral replication. The human lung 
cancer epithelial cell line A549 was used as a reference, since it is commonly used to 
propagate different adenovirus serotypes (114). Furthermore, several leukocyte cell 
lines including the human monocyte cell line U937, the B lymphocytes-derived 
Burkitt’s lymphoma cell line BJAB, as well as the human acute monocytic leukemia 
cell line THP-1 were used. These cell lines were selected based on previous studies 
showing the ability of adenovirus to establish latent infections in leukocytes (115, 
116). As it was shown for other viruses, that latency can be accompanied by a 
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specialized miRNA expression pattern, these cell lines were of particular interest for 
these studies. A cell-type specific miRNA patterns could give rise to differences in the 
adenoviral infection cycle. Therefore, the establishment of a latent infection may be 
preferred. To optimize cell culture conditions for efficient virus replication, several 
parameters were considered. 
In a series of experiments the different cell lines were infected with an EGFP 
gene-harboring adenoviral vector as described in the “Materials and Methods” 
section. At 24 hours post-infection, FACS analysis was conducted on mock- or EGFP 
transduced cells. The percentage of EGFP-positive cells directly correlates with the 
rate of infection. An obvious difference in the required MOI to obtain equal infection 
rates could be observed (Fig. 14). In A549 cells a MOI of 50 is high enough to infect 
almost the entire cell population. However this is different for the leukocyte cell lines 
BJAB and THP-1, since in these cases a much higher number of infectious particles 
per cell is required to obtain infection rates as high as in A549 cells. Furthermore, the 
U937 cell line could not be infected at all and was thus excluded from further 
analysis.  
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Figure 14: Flow cytometric analysis of different cell lines, infected with an EGFP gene-
carrying adenoviral vector. All measurements were performed 24 hours post-infection. The 
infection was carried out at different multiplicities of infection (MOI) and the percentage of 
EGFP-positive cells indicates the infection efficiency. The figure shows infection efficiencies 
of adenovirus 5 in A549 cells (upper left panel), in the B cell lymphoma cell line BJAB (upper 
right panel), in the human acute monocytic leukemia cell line THP-1 (lower left panel) and in 
the pro-monocytic cell line U937 (lower right panel). 
 
6.3.2 Infection kinetics of adenovirus type 5 wild-type and ΔVA RNA 
 
Since expression of VA RNAs would presumably diminish miRNA-mediated silencing 
of adenoviral gene products I used a double mutant of Ad5 lacking the VA RNAI as 
well as the VA RNAII genes. This mutant is referred to as dl-sub720 (Ad5 ΔVA) and 
has been described previously (60, 117, 118). In order to examine the differences in 
the gene expression pattern between Ad5 wild-type and Ad5 ΔVA, I performed 
analysis of their infection kinetics in the different cell lines. This experiment allowed to 
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monitor changes in steady-state mRNA levels of adenoviral transcripts derived from 
either Ad5 wild-type or Ad5 ΔVA.  
A549, BJAB, and THP-1 cells were seeded and infected as described in 
“Materials and Methods”. At different time points after infection, samples were taken 
and the expression rates of the adenoviral genes coding for E1A 13S, E1A 9S, E1B 
RNA4, E1B RNA5, E3, E4, IVa2, Hexon, pTP, DNA-binding protein (DBP), precursor 
terminal protein (pTP) and DNA polymerase (Pol) were determined by RT-qPCR. 
Due to the onset of a strong cytopathic effect, which eventually results in cell lysis, 
the latest time point for harvesting of Ad5 wild-type infected A549 cells was restricted 
to 48 hours post-infection. The onset of cytopathic effect was delayed when Ad5 ΔVA 
was used. Even 96 hours post-infection, most of the A549 cells were attached to the 
surface of the cell culture dish. Accordingly, obvious differences in the infection 
kinetics were observed (Fig. 15). The increase of steady-state levels of viral 
transcripts was slowed down when the mutant was used. Furthermore the overall 
mRNA levels were substantially lower compared to the abundance of Ad5 wild-type 
transcripts, even during the late phase of infection.  
67 
 
 
Figure 15: Expression kinetics of Ad5 wild-type and Ad5 ΔVA in A549 cells. mRNA 
levels are shown as the relative amount of the housekeeping gene GAPDH. E1A 13S, E1A 
9S, E1B RNA4, E1B RNA5, E3, E4, IVa2, Hexon, pTP, DNA-binding protein (DBP), 
precursor terminal protein (pTP) and polymerase (Pol) mRNA levels were determined by RT-
qPCR. (n = 2; mean values ± SD) 
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Although infected at a higher multiplicity of infection, the steady state mRNA levels of 
all transcripts were slightly lower compared to A549 cells, when THP-1 and BJAB 
cells were used. However, the infection kinetics in BJAB and THP-1 cells were not 
remarkably different from A549 cells with the exception that the increase in steady-
state levels of the transcripts was slowed down (Data not shown). I measured RNA 
levels of E1A13S and hexon as representative genes to assess the differences 
between Ad5 wild-type and Ad5 ΔVA. When BJAB cells were infected with Ad5 ΔVA, 
the steady-state mRNA levels of viral transcripts were even lower. In THP-1 cells, the 
increase of transcript levels was delayed, however reaching comparable amounts at 
the end of the measurement series (Fig. 16).  
 
Figure 16: Infection kinetics of Ad5 wt compared to Ad5 ΔVA. BJAB (A) and THP-1 (B) 
cells were used. Amounts of E1A 13S and Hexon mRNA were normalized to housekeeping 
gene GAPDH.    (n = 2; mean values ± SD) 
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6.3.3 Prediction of target sites for cellular miRNAs in the adenoviral genome 
 
To screen for putative binding sites of cellular miRNAs in the human adenovirus type 
5 genome (NCBI Reference Sequence: AC_000008.1) I used the TargetScan 
prediction software. For identification of miRNA target sites locates on viral 
transcripts, such an approach is disadvantageous, as it can neither account for 
actually transcribed regions, nor different transcript variants, such as differentially 
spliced mRNAs. Nevertheless, this kind of analysis provided a first impression of the 
distribution of target sites throughout the genome. To filter the software output, a 
histogram-based threshold was introduced (“Appendix”). Predictions below a context 
score of 0.15 were selected for further analysis. To assess the distribution of the 
predicted target sites, the context scores were plotted against their respective 
position in the genome (Fig. 2B). This revealed an unequal distribution of the target 
sites, showing the majority of hits located in proximity to the terminal repeats on both 
sites of the genome. However, almost every transcription unit was predicted to be 
presumably subject to cellular miRNA targeting.  
 
6.3.4 Adenoviral transcripts targeted by miRNAs in Ad5 ΔVA-infected cells 
 
Next, I used the RIP-assay as an additional method to screen for viral mRNAs 
targeted by cellular miRNAs. Therefore, A549, BJAB and THP-1 cells were infected 
with Ad5 ΔVA. Media was exchanged at 4 hours post-infection and cells were 
subjected to a RIP-assay at 48 hours post-infection. This time point was chosen in 
accordance with the infection kinetic studies, expecting adequate mRNA levels for 
each viral transcript present in infected cells to not fall below the detection limit of the 
RIP-assay. After RNA amplification, RT-qPCR assays were performed to determine 
the enrichment of mRNAs as described previously.  
Interestingly, I was able to observe enrichments for several mRNAs, most of 
them encoding proteins expressed during the late phase of infection (Fig. 17). This 
finding would support the hypothesis, that adenoviral mRNAs are indeed targeted by 
cellular miRNAs. Since a number of target sites identified by TargetScan were 
distributed over the region transcribed from the major late promoter, this result would 
also be in line with the bioinformatics approach. 
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Furthermore, the pattern of enriched mRNAs was different in the distinct cell 
types. For example, the pTP mRNA was found ~8-fold enriched in A549 cells 
compared to the input steady-state level. This enrichment was significantly lower in 
BJAB and THP-1 cells. Furthermore, in THP-1 cells, the hexon mRNA showed the 
highest enrichment. This was not true for BJAB cells, in which the hexon, the DPB 
and the IVa2 transcripts were equally enriched as DBP and IVa2. These different 
levels of enrichment in distinct cell types may be simply explained by their different 
miRNA expression pattern.  
 
 
Figure 17: RIP-assay analysis of A549, BJAB and THP-1 cells infected with Ad5 ΔVA. 
24 hours post-infection cells were subjected to RIP-assay. The left panels show relative 
mRNA levels of distinct adenoviral gene products in the total cell lysate determined by RT-
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qPCR. Fold-enrichments of mRNA in the IP fraction over mRNA levels detected in total cell 
lysates are depicted in the right panel. All CT values were normalized to the respective 
GAPDH values (n = 2; mean values ± SD). 
 
6.3.5 Adenoviral transcripts targeted by miRNAs in adenovirus type 5 wild-
type-infected cells 
 
Finally I wanted to test whether adenoviral transcripts are targeted by miRNAs in the 
presence of VA RNAs. Therefore I repeated the experiment using Ad5 wt and A549 
cells. At 30 hours post-infection, RIP-assays were performed and mRNA enrichments 
were determined by RT-qPCR (Fig. 18).  
I could observe moderate enrichments over input for E1B mRNA4, E1B 
mRNA5 and IVa2. However, the enrichment of other mRNAs such as pTP, Hexon 
and the ML transcripts could not be reproduced. This outcome is highly interesting, 
since it is in line with the hypothesis, that the VA RNAs may provide a molecular 
shield to protect adenoviral mRNA from RNAi-mediated silencing. It is conceivable 
that in particular the late transcripts will benefit from such a protective function. 
Interestingly, some of them (i.e. hexon, ML, DBP, pTP) were found higher enriched, 
compared to RNAs encoded by early genes, when the virus lacking the VA RNAs 
was used. No such difference in the enrichment rate between early and late 
transcripts was observed for Ad5 wild-type.  
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Figure 18: RIP-assay analysis of A549 cells infected with Ad5 wild-type. 30 hours post-
infection cells were subjected to RIP-assay. The left panel shows relative mRNA levels of 
distinct adenoviral gene products in the total cell lysate determined by RT-qPCR. Fold 
enrichments of mRNA in the IP fraction over mRNA levels obtained from total cell lysates are 
depicted in the right panel. All CT values were normalized to the respective GAPDH values.  
(n = 2; mean values ± SD) 
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7 Discussion 
 
This study provides a comprehensive in vitro analysis of the molecular interactions 
between adenovirus-encoded RNAs and components of the host cell RNAi pathway. 
I made use of several methods to shed light on this poorly understood interplay.  
The studies were initiated by the observation that the replication of adenovirus 
is disturbed when lacking genomic regions encoding the VA RNAs (59). The reason 
for such an impairment of the reproductive cycle might be multifactorial. Cellular 
antiviral defense mechanisms such as the induction of PKR-mediated inhibition of 
translation can be overcome by VA RNA expression (57, 62, 63). Furthermore, 
oversaturation of Dicer, Exportin-5 and RISC, the central components of RNA 
interference may be of particular importance for a successful virus replication (7). 
Since it is known that cellular RNAi can induce the degradation of viral mRNAs (82), 
antagonizing this other branch of antiviral defense would be reasonable (Fig. 19).  
The saturation of RISC implies an efficient incorporation of VA RNA-derived 
mivaRNAs. This renders it likely that these miRNA-like molecules can also act as 
effectors of RNAi by targeting cellular mRNAs. Evidence for such mechanism was 
provided by Aparicio et al. (2010). Microarray expression analysis revealed a distinct 
set of genes downregulated upon transfection of the VA RNA-expressing vector 
pAdVantage (64). The authors could demonstrate the interaction between the 
mivaRNAs and selected candidate mRNAs. However, given the fact that miRNA-
mediated gene silencing occurs not only by mRNA reduction, but also by translational 
repression, several mivaRNA targets may have been missed (98). 
To unravel the implication of mivaRNA expression, I have employed an 
innovative biochemical approach. First, I transfected A549 cells with mivaRNA 
mimics, and by using a monoclonal antibody against cellular Argonaute proteins, I 
performed immunoprecipitation of RISC complexes. This approach allows direct 
isolation of co-immunoprecipitating miRNAs and their target mRNAs. Microarray 
analysis of captured mRNAs revealed a set of target mRNAs involved in various 
biological functions.  
The putative mivaRNA target lymphocyte antigen 6 complex, locus K (LY6K), 
identified by Aparicio et al. (2010) could be confirmed in this study; however the list of 
top candidate genes showed only little overlap. 
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Although its functions are not entirely understood, it is anticipated that 
members of the LY6 family are involved in the susceptibility to adenovirus infections 
in mice. LY6 expression can be induced by Interferons and high levels are found in 
infected tissue, suggesting an immunomodulatory function (119 and references 
therein). Furthermore, genetic heterogeneity of the LY6 locus was linked to HIV-1 
(120) and West Nile virus (121) susceptibility. Taken together, a specific pattern of 
Ly6 proteins may be beneficial for virus replication. Our data suggest that targeting of 
the member LY6K may be particularly advantageous for the promotion of the 
adenovirus infection cycle.   
Another target which I was able to identify in this study, and which is 
particularly interesting is the alpha subunit of Interleukin 12. This immunoregulatory 
cytokine is produced by antigen presenting cells and is involved in a broad range of 
biological mechanisms. Its first proposed function was to activate the cytotoxic 
function of Natural Killer (NK) cells. However, it has later also been found to activate 
the production of Interferon-ɣ in T cells and NK cells (122, 123). Another function 
concerns the differentiation of T helper (TH) cells. The latter can differentiate into 
distinct cellular subsets. Two major forms are termed TH1 and TH2 cells and are 
characterized by differences in cytokine production (124, 125). The functions of TH1 
cells involve the promotion of cell-mediated immunity and the coordination of immune 
responses against intracellular invaders such as viruses. On the other hand TH2 cells 
are promoting humoral immune responses, directed against extracellular pathogens 
(125 and references therein). IL-12 encourages the development of TH1 cells from 
precursor cells and thus acts as a master regulator of the appropriate immune 
response to pathogens (126). It has been shown by transcriptome analysis, that IL-
12A expression is downregulated in the presence of adenovirus (127). The current 
study suggests that this downregulation can be at least partially attributed to gene 
silencing mediated by mivaRNAs. This could be interpreted as a mechanism to 
counteract host defense mechanisms by attenuating the cellular-immune response.  
The putative target Galectin-3, which is encoded by the LGALS3 gene has 
multiple extracellular and intracellular functions and a control of its expression might 
constitute an additional possibility for the virus to influence the regulation of cell cycle, 
signaling, apoptosis and immune response. A detailed review on the spectrum of 
function of this master-regulator can be found in reference 128. 
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Other genes such as the guanylate kinase 1 (GUK1) or the N-
acetyltransferase 14 are involved in metabolic processes. The deregulation of the 
host cell metabolism during infection has already been identified in other studies and 
may enhance the efficiency of viral replication. The same is true for molecules 
functioning in signaling pathways such as the G-protein signaling molecule GPR63  
or  CRIPAK and SRI, which may be targeted to deregulate the cellular gene 
expression (127). The regulation of the expression of these genes by mivaRNAs is 
an interesting finding, as it apparently represents an additional layer of complexity in 
terms of host-virus interactions. 
Little is known about the function of other targets. For example the 
transmembrane protein 222 which is encoded by the TMEM222 gene is not well 
characterized. However, the finding that it possibly represents a target of mivaRNA 
may be valuable piece of information for subsequent studies.  
 In summary, our findings suggest that mivaRNAs have a broad range of 
cellular target genes. This RNAi-mediated regulatory mechanism might aid the 
establishment of an adenoviral infection. During the fight between the virus and its 
host cell, the virus strives to gain control over different biological processes such as 
the immune response, cellular metabolism and different signaling pathways. This 
goal may be in part achieved by expressing mivaRNAs and is reflected by the variety 
of the proposed functions for the putative target genes. A challenge for the future will 
be their further validation and a deepened analysis of their functions in the virus 
replicative cycle. This study can serve as a basis for further investigations of these 
molecular mechanisms.  
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Figure 19: Summary of the proposed functions of VA RNAs. (A) VA RNAs are 
transcribed and give rise to different mivaRNAs which are incorporated into RISC 
(mivaRISC). These complexes can target cellular mRNAs and finally repress their translation 
or induce their degradation. (B) In the absence of VA RNAs, viral mRNAs are targeted by 
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cellular miRNAs which may result in an impaired synthesis of viral proteins. (C) mivaRNAs 
are saturating RISC which may protect viral mRNAs from cellular miRNA-mediated targeting. 
This may enhance the translation efficiency of viral proteins and promote virus replication. 
 
In the last part of the study I aimed at the elucidation of the protective function of VA 
RNAs on viral mRNAs by using a mutant virus lacking the VA RNA genes. The 
infection rate of different cell lines was obviously decreased compared to the wild-
type virus and analysis of its infection kinetics revealed diminished steady-state 
mRNA levels of distinct viral gene products. This indicates that an inhibitory and 
probably cellular mechanism affects the abundance of adenoviral transcripts. It is 
conceivable that that these differences in infection kinetics arise at least partially due 
to a loss of protection against targeting by cellular miRNAs. 
I employed bioinformatic analysis to screen for putative target sites of cellular 
miRNAs in the adenovirus genome. Some of these predictions could be confirmed by 
using the biochemical RIP-assay combined with RT-qPCR. When comparing Ad5 
wild-type and Ad5 ΔVA, several mRNAs were found to be enriched in RISC. 
Strikingly, when the mutant virus was used, mRNAs transcribed during the late phase 
of infection were predominantly enriched. This effect was not observable when the 
wild-type virus was used. This finding would be in line with the literature, as it was 
shown that especially during the late phase of infection, expression of the VA RNAs 
is required to allow efficient translation of the viral mRNAs (59)  
Interestingly, the pattern of viral transcripts associated with RISC was slightly 
different in distinct cell types. This might be due to a different, cell-type specific 
miRNA expression pattern.  
Conducting the same experiment on cells infected with Ad5 wild-type revealed 
no enrichment for the hexon and the major late transcripts compared to early 
transcripts. This may have various reasons. For example, since E1B gene expression 
is initiated early during infection, translational repression of E1B gene expression by 
cellular miRNAs could occur even before the VA RNAs are efficiently expressed. In 
this case, translation of these mRNAs would be silenced already during the early 
phase of infection. Another explanation may be the activity of highly abundant 
miRNAs, which may still be present in active RISC during late phases of infection and 
target viral mRNAs. Finally, a third explanation may be that viral mRNAs are targeted 
by mivaRNAs themselves in a regulatory manner. Such an interaction would also 
lead to an enrichment in RISC and can thus not be excluded by the approach I have 
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used. Nevertheless, these suggestions are rather speculative and the results have to 
undergo further validation.  
The major bottleneck of this approach is its limited comprehensiveness. Viral 
primary transcripts, such as the major late transcript, are processed into several 
mRNAs. Restricting the analysis to RT-qPCR assays used in this study, does not 
allow distinguish between all distinct mRNA species generated from the primary 
transcripts. Furthermore, several low abundant transcripts would presumably fall 
below the detection limit. The application of a combined approach including 
computational methods, RIP-assays coupled to RT-qPCR and deep sequencing will 
be necessary to re-evaluate and to further interpret the data presented here.  
Taken together, the results of this work provide further insight into the interplay 
between adenovirus and the cellular RNAi machinery. The expression of VA RNAs 
presumably act as molecular shields to protect viral transcripts form miRNA-mediated 
decay, and additionally may also actively interfere with a variety of cellular processes 
such as the immune response to contribute to a successful infection of the host 
organism (Fig. 19).  
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10 Appendix 
 
 
Predicted cellular miRNAs targeting the adenoviral genome. Histogram showing 
the distribution of context score values for predicted target sites of cellular miRNAs in 
the human Ad5 genome calculated by TargetScan. A class width of 0.01 was used. A 
context score below -0.16 was assigned to 5 % of the putative binding sites. These 
were plotted against the relative position in the genome (Fig. 2B).  
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Annealing of mivaRNA mimics. After annealing of the single stranded RNA 
oligonucleotides as described in „Materials and Methods“, the migration behavior was 
assessed by agarose gel electrophoreses using a 4% agarose gel. The single 
stranded RNA oligonucleotides mivaRNA(A)I-137 AS and mivaRNA(G)I-137 AS 
showed slower migrations, which may be due to secondary structure formation. A 
different migration behavior was observed after annealing indicating successful 
annealing.  
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mivaRNA target vectors. The target sequences of the mivaRNA mimics were 
inserted into SgfI and NotI sites of the psiCHECKTM-2 vector. The exact sequences 
are listed below: 
 
pmiVAI5-T 
GCGATCGCCATATGACCGGTACCAGACCACGGAAGAGTGCCCGCTACCGGTGAGCTCGTCGACGCGGCCGC 
pmiVAI3-T 
GCGATCGCCATATGACCGGTAAAAGGAGCACTCCCCCGTTGTCTGACCGGTGAGCTCGTCGACGCGGCCGC 
pmiVAII5-T 
GCGATCGCCATATGACCGGTTCCGGCTACAGGGAGCGAGCCACCGGTGAGCTCGTCGACGCGGCCGC 
pmiVAII3-T   
GCGATCGCCATATGACCGGTGGGGCTCGTCCCTGTTTCCGACCGGTGAGCTCGTCGACGCGGCCGC 
Yellow: SgfI 
Red: NdeI 
Pink: AgeI 
Light blue: SacI 
Dark green: SalI 
Light green: NotI 
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Map of the pAdVAntageTM Vector. The pAdVAntageTM vector was used for 
transfection of mammalian cells. It contains the VA RNAI and the VA RNAII genes. 
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